Solid forms of a KRAS inhibitor and uses thereof
Crystalline forms of the KRAS inhibitor address solubility and stability issues, enhancing pharmacokinetics and reducing adverse effects, thereby improving drug absorption and bioavailability.
Patent Information
- Application Number
- PCT/US2026/027949
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-13
- Filing Date
- 2026-05-13
- Publication Date
- 2026-11-19
AI Technical Summary
Existing KRAS inhibitors face challenges with poor aqueous solubility, slow dissolution rate, poor stability at physiological pH, poor permeation through biomembranes, extensive presystemic metabolism, and inadequate systemic absorption, leading to inconsistent drug levels and adverse effects like diarrhea and emesis.
Development of crystalline forms of the KRAS inhibitor 2-Amino-4-(3-((S)-3-(dimethylamino)pyrrolidin-1-yl)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-6-yl)-7-fluorothieno[3,2-c]pyridine-3-carbonitrile and its pharmaceutically acceptable salts, such as esylate and hydrochloride, which provide improved solubility, stability, and reduced adverse effects.
The crystalline forms enhance pharmacokinetic profiles with reduced variability and minimize side effects like emesis, offering consistent drug absorption and bioavailability.
Smart Images

Figure US2026027949_19112026_PF_FP_ABST
Abstract
Description
[0001]
[0002] SOLID FORMS OF A KRAS INHIBITOR AND USES THEREOF
[0003] Technical Field
[0004] [1] The present disclosure is directed to solid forms of 2-Amino-4-(3-((S)-3- (dimethylamino)pyrrolidin-l-yl)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-6-yl)-7- fluorothieno[3,2-c]pyridine-3-carbonitrile, including pharmaceutically acceptable salts thereof, as well as crystalline forms of the salts, and use thereof for the treatment of disease. The present disclosure also relates to pharmaceutical compositions comprising the novel salts and crystalline forms thereof, and methods of treating disease.
[0005] Background
[0006] [2] Therapeutic agents can be administered to patients via different routes, including oral, intravenous, and subcutaneous. Oral dosing of therapeutics offers multiple advantages over other routes of administration. For example, orally delivered drugs are easily self-administered, thereby resulting in increased patient compliance and obviating the requirement for specialized delivery devices for injectable or inhaled therapies or delivery in a therapeutic setting. Moreover, oral administration is typically the safest route of getting a drug into the body since it does not require complicated devices or puncturing of body surfaces or membranes.
[0007] [3] Despite the advantages offered by oral dosing, obtaining consistent and adequate circulating levels of drug with oral dosing can be challenging due to, among other things: poor aqueous solubility; slow dissolution rate in biological fluids; poor stability of drug at physiological pH; poor permeation through biomembranes; extensive presystemic metabolism; and inadequate or inconsistent systemic absorption between individuals or within specific regions of the gastrointestinal system. From a safety standpoint, minimizing the total dosage requirement for efficacy as well as reducing variability in absorption should allow for fewer unwanted side effects such as diarrhea and emesis, commonly called vomiting.
[0008] [4] Oncogenic KRAS mutations have been identified in approximately 30% of human cancers and have been demonstrated to activate multiple downstream signaling pathways.
[0009] Despite the prevalence of KRAS mutations, it has been a difficult therapeutic target. (Cox, A.D. Drugging the Undruggable RAS: Mission Possible? Nat. Rev. Drug Disc. 2014, 13, 828-851; Pylayeva-Gupta, y et al. RAS Oncogenes: Weaving a Tumorigenic Web. Nat. Rev. Cancer 2011, 11, 761-774).
[0010] [5] WO2024 / 206766 discloses KRAS inhibitors, including 2-Amino-4-(3-((S)-3-
[0011]
[0012] (dimethylamino)pyrrolidin-l-yl)-5-fluoro-7,9-dihydrofurol3,4-fJquinazolin-6-yl)-7- fluorothieno[3,2-c]pyridine-3-carbonitrile, which has the following structure:
[0013] H2N
[0014]
[0015] WO2024 / 206766 as an amorphous, free base compound (hereinafter “Formula II”).
[0016] [61 Polymorphism is the ability of a substance to crystallize in more than one crystal lattice arrangement. Crystallization, or polymorphism, can influence many aspects of the solid-state properties of a drug substance. A crystalline substance may differ considerably from an amorphous form, and different crystal modifications of a substance may differ considerably from one another in many respects including solubility, dissolution rate and / or bioavailability.
[0017] Generally, it is difficult to predict whether a given compound will form any crystalline solid-state forms. It is even more difficult to predict the physical properties of these crystalline solid-state forms.
[0018] [7] Therefore, it can be advantageous to have crystalline forms of the compound of Formula II and its salts. In particular, there remains a need to provide a form of the compound of Formula II with suitable solubility and / or stability and alternate methods of preparing the compound.
[0019] Further, there is a need to provide pharmaceutical compositions comprising the compound or a pharmaceutically acceptable salt thereof that provide an improved pharmacokinetic profile with reduced or minimized untoward or undesired effects, such as emesis or diarrhea. The present disclosure addresses one or more of these needs by providing novel crystalline forms of the compound of Formula II and / or pharmaceutical compositions comprising the compound or a pharmaceutically acceptable salt thereof.
[0020] Summary
[0021] [8] In one embodiment, provided is a solid form of a compound of Formula II:
[0022] N
[0023]
[0024] Formula II,
[0025]
[0026] which includes a salt, as well as a crystalline form of the salt. In one embodiment, provided are pharmaceutically acceptable salts of Formula II, and solid forms thereof. Examples of pharmaceutically acceptable salts of Formula II include hydrochloride salt, mesylate salt, tosylate salt, besylate salt, esylate salt, and sulfate salt.
[0027] [9] In one embodiment, provided is an esylate salt of a compound of the formula:
[0028]
[0029] esylate salt is of the formula:
[0030]
[0031] Formula I.
[0032] The chemical name for Formula I can be written as 2-Amino-4-(3-((S)-3- (dimethylamino)pynolidin-l-yl)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-6-yl)-7- fluorothieno[3,2-c]pyridine-3-carbonitrile ethanesulfonate. An alternative chemical name for Formula I is 2-Amino-4-(3-((S)-3-(dimethylamino)pyrrolidin4-yl)-5-fluoro-7,9-dihydrofuro[3,4- f]quinazoIin-6-yl)-7-fluorothieno[3,2-c]pyridine-3-carbonitrile esylate. In one embodiment, the compound of Formula I is in crystalline form.
[0033]
[0010] In another embodiment, provided is a hydrochloride salt of a compound of the formula:
[0034]
[0035] hydrochloride salt is of the formula:
[0036]
[0037] Formula III.
[0038] The chemical name for Formula III can be writen as 2-Amino-4-(3-((S)-3- (dimethylamino)pyrrolidin-l-yl)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-6-yl)-7- fluorothieno[3,2-c]pyridine-3-carbonitrile hydrochloride. In one embodiment, the compound of Formula III is in crystalline form.
[0039]
[0011] In another embodiment, provided herein are orally administrable, pharmaceutical compositions comprising the compounds disclosed herein. In one embodiment, the orally administrable, pharmaceutical compositions are enterically coated.
[0040]
[0012] In another embodiment, provided are therapies including the compounds disclosed herein, for the treatment of diseases, such as cancer.
[0041]
[0013] In another embodiment, provided are therapies including the pharmaceutical compositions disclosed herein, for the treatment of diseases, such as cancer.
[0042]
[0014] In another embodiment, provided are processes of making crystalline forms of Formula II.
[0043] Brief Description of the Figures
[0044]
[0015] Figure 1 is an XRPD chromatogram of crystalline 2-Amino-4-(3-((S)-3- (dimethylamino)pyrrolidin-l-yl)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-6-yl)-7- fluorothieno[3,2-c]pyridine-3-carbonitrile (crystalline Formula II).
[0045]
[0016] Figure 2 is an XRPD chromatogram of crystalline 2-Amino-4-(3-((S)-3- (dimethylamino)pyrrolidin-l-yl)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-6-yl)-7- fluorothicno[3,2-c]pyridinc-3-carbonitrilc cthancsulfonatc (crystalline Formula I).
[0046]
[0017] Figure 3 is an XRPD chromatogram of crystalline 2-Amino-4-(3-((S)-3- (dimethylamino)pyrrolidin-l-yl)-5-fluoro-7,9-dihydrofuro[3,4-f|quinazolin-6-yl)-7- fluorothieno[3,2-c]pyridine-3-carbonitrile hydrochloride (crystalline Formula III).
[0047] Detailed Description
[0048]
[0018] The present disclosure relates to new solid forms of the pan- KRAS inhibitor 2-amino-4-(3-
[0049]
[0050] ((S)-3-(dimethylamino)pyrrolidin-l-yl)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-6-yl)-7- fluorothieno[3,2-c]pyridine-3-carbonitrile (i.e., Formula II, see below). One skilled in the art understands that a compound structure may be named or identified using commonly recognized nomenclature systems and symbols. By way of example, the compound may be named or identified with common names, systematic or non-systematic names. The nomenclature systems and symbols that are commonly recognized in the art of chemistry including but not limited to Chemical Abstract Service (CAS) and International Union of Pure and Applied Chemistry (IUPAC). Accordingly, the compound structure for Formula II provided above may also be named or identified as thieno[3,2-c]pyridine-3-carbonitrile, 2-amino-4-[3-[(3S)-3- (dimethylamino)-l-pyrrolidinyl]-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-6-yl]-7-fluoro.
[0051]
[0019] In some embodiments, provided herein are solid forms (e.g., crystalline forms) of Formula II. In some embodiments, provided herein are crystalline forms of Formula II and pharmaceutically acceptable salts thereof, and methods of preparing the crystalline forms of the compound. Further, the present disclosure is directed to pharmaceutical compositions comprising the compounds disclosed herein that provide an improved pharmacokinetic profile with reduced or minimized untoward or undesired effects, such as emesis or diarrhea.
[0052]
[0020] In some embodiments, the present disclosure provides pharmaceutical compositions (e.g., enteric capsule, enteric tablet) comprising a compound disclosed herein. In some embodiments, the pharmaceutical compositions disclosed herein may reduce the frequency of emesis without substantial impact on exposure by delivering the compound disclosed herein to the upper- gastrointestinal tract. In some embodiments, the pharmaceutical compositions comprising a compound disclosed herein show improved pharmacokinetics (e.g., lower compound variability and higher exposure of the compound in the subjects). In some embodiments, no emesis (or reduced frequency of emesis) is observed in the subjects that receive the pharmaceutical compositions comprising a compound disclosed herein.
[0053]
[0021] As used herein, “compound disclosed herein’’ or “compounds disclosed herein” refer to any compound disclosed in the present disclosure, including amorphous form of Formula II, amorphous salts of Formula II, crystalline free base forms of Formula II (e.g., crystalline Formula II), and crystalline salts of Formula II (e.g., crystalline Formula I, crystalline Formula III). Exemplary salts of the compounds disclosed herein include hydrochloride salt, methanesulfonic acid salt (mesylate salt), toluenesulfonic acid salt (tosylate salt), benzenesulfonic acid salt (besylate salt), ethanesulfonic acid salt (esylate salt), and sulfate salt. In
[0054]
[0055] one embodiment, the compound is Formula I. In one embodiment, the compound of Formula 1 is in crystalline form (i.e., crystalline Formula I). In one embodiment, the compound is Formula II. In one embodiment, the compound of Formula II is in crystalline form (i.e., crystalline Formula II). In one embodiment, the compound is Formula III. In one embodiment, the compound of Formula III is in crystalline form (i.e., crystalline Formula III).
[0056]
[0022] As used herein, the terms “crystal form” and “crystalline form” interchangeably refer to a crystal structure (or polymorph) having a particular molecular packing arrangement in the crystal lattice. Crystalline forms can be identified and distinguished from each other by one or more characterization techniques including, for example, X-ray powder diffraction (XRPD), single crystal X-ray diffraction, differential scanning calorimetry (DSC), dynamic vapor sorption (DVS), and / or thermogravimetric analysis (TGA). Accordingly, as used herein, the terms “compound of Formula I is in crystalline form” , “compound of Formula II is in crystalline form,” and “compound of Formula III is in crystalline form” refer to unique crystalline forms that can be identified and distinguished from each other by one or more characterization techniques including, for example, X- ray powder diffraction (XRPD), single crystal X-ray diffraction, and / or differential scanning calorimetry (DSC). In some embodiments, the novel crystalline forms are characterized by an X- ray powder diffractogram having one or more signals at one or more specified two-theta values (° 29).
[0057]
[0023] As used herein, the term “about” is intended to refer to an acceptable degree of error for the amount or quantity indicated given the nature or precision of the measurements. For example, the degree of error can be indicated by the number of significant figures provided for the measurement, as is understood in the art, and includes but is not limited to a variation of + / -1 in the most precise significant figure reported for the amount or quantity. Typical exemplary degrees of error are within 20 percent (%), preferably within 10%, and more preferably within 5% of a given value or range of values. For instance, “about” may mean the numeric value may be modified by ±5%, ±4%, ±3%, ±2%, ±1%, ±0.5%, ±0.4%, ±0.3%, ±0.2%, ±0.1% or ±0.05%. Numeric values modified by the temr “about” include the specific identified value. For example, “about 5.0” includes 5.0.
[0058]
[0024] The term “ethanesulfonic acid salt” (“esylate salt”) includes mono-ethanesulfonic acid salt and di-cthancsulfonic acid salt. In one embodiment, the compound disclosed herein is a monoethanesulfonic acid salt (i.e., Formula I). In some embodiments, Formula II is combined with about 1 to about 2 molar equivalents of ethanesulfonic acid. In some embodiments. Formula II is
[0059]
[0060] combined with about 1.1 to about 1.5 molar equivalents of ethanesulfonic acid.
[0061]
[0025] The term “hydrochloride salt” includes hemi-HCl salt, mono-HCl salt, and di-HCl salt. In one embodiment, the compound disclosed herein is a mono-HCl salt (i.e., Formula III).
[0062]
[0026] The use of certain solvents and / or processes have been found to produce different crystalline forms of Formula II which may exhibit one or more of the favorable characteristics described above. The processes for the preparation of the crystalline forms described herein and characterization of these crystalline forms are described in detail below.
[0063] Solid forms of Formula II
[0064]
[0027] In some embodiments, Formula II can be isolated in crystalline form.
[0065]
[0028] In some embodiments, Formula II can be isolated as a salt which can be amorphous or crystalline. In some embodiments, the salt is amorphous. In some embodiments, the salt is crystalline. In some embodiments, Formula II can be isolated as a hydrochloride salt, mesylate salt, tosylate salt, besylate salt, esylate salt, and sulfate salt. In some embodiments, the salt is a hydrochloride salt. In some embodiments, the salt is a mesylate salt. In some embodiments, the salt is a tosylate salt. In some embodiments, the salt is a besylate salt. In some embodiments, the salt is an esylate salt. In some embodiments, the salt is a sulfate salt. In some embodiments, the compound of Formula II is a crystalline hydrochloride salt. In some embodiments, the compound of Formula II is a crystalline mesylate salt. In some embodiments, the compound of Formula II is a crystalline tosylate salt. In some embodiments, the compound of Formula II is a crystalline besylate salt. In some embodiments, the compound of Formula II is a crystalline esylate salt. In some embodiments, the compound of Formula II is crystalline sulfate salt.
[0066]
[0029] In some embodiments, disclosed herein is a crystalline free base form of a compound of the formula:
[0067] N S J INN F
[0068]
[0069] characterized by having an X-ray powder diffraction (XRPD) pattern comprising a peak in degrees at 20 value of 7.2 ± 0.2. In some embodiments, the crystalline form of the compound (i.e., crystalline Formula II) is characterized by having an X-ray powder diffraction (XRPD) pattern
[0070]
[0071] further comprising peaks in degrees at 20 values of 15.5 + 0.2 and 19.9 + 0.2. In some embodiments, the crystalline form of the compound (i.e., crystalline Formula II) is characterized by having an X-ray powder diffraction (XRPD) pattern having at least one peak in degrees at 20 value selected from 7.2± 0.2, 11.7± 0.2, 13.3±0.2, 14.6±0.2, 15.5±0.2, 17.2±0.2, 18.5±0.2, 19.2± 0.2, 19.9+ 0.2, 25.1 + 0.2, and 25.8+ 0.2. In one embodiment, the crystalline form of the compound (i.e., crystalline Formula II) is characterized by having an X-ray powder diffraction (XRPD) pattern having a peak in degrees at 20 value of 7.2 + 0.2 in combination with at least one peak in degrees at 20 selected from 11.7± 0.2, 13.3± 0.2, 14.6± 0.2, 15.5± 0.2, 17.2± 0.2, 18.5± 0.2, 19.2± 0.2, 19.9± 0.2, 25.1± 0.2, and 25.8± 0.2.
[0072]
[0030] In some embodiments, disclosed herein is an esylate salt of a compound of the formula:
[0073]
[0074] the esylate salt is of the formula:
[0075]
[0076] the esylate salt is in crystalline form.
[0077]
[0031] In some embodiments, disclosed herein is a crystalline form of a salt of the formula:
[0078]
[0079] characterized by having an X-ray powder diffraction (XRPD) pattern comprising a peak in degrees at 20 value of 16.1 + 0.2. In some embodiments, the crystalline salt form (i.e., crystalline Formula I) is characterized by having an X-ray powder diffraction (XRPD) pattern further comprising peaks in degrees at 20 values of 7.7 ± 0.2 and 13.5 ± 0.2. In some embodiments, the crystalline salt form (i.e., crystalline Formula I) is characterized by having an X-ray powder
[0080]
[0081] diffraction (XRPD) pattern having at least one peak in degrees at 20 value selected from 6.3+ 0.2, 7.7+ 0.2, 13.0+ 0.2, 13.5+ 0.2, 15.5+ 0.2, 16.1+ 0.2, 16.9+ 0.2, 19.1+ 0.2, 22.6+ 0.2, 23.3+ 0.2, 24.3+ 0.2, and 26.2+ 0.2. In one embodiment, the crystalline salt form (i.e., crystalline Formula I) is characterized by having an X-ray powder diffraction (XRPD) pattern having a peak in degrees at 20 value of 16.1 + 0.2 in combination with at least one peak in degrees at 20 selected from 6.3+ 0.2, 7.7+ 0.2, 13.0+ 0.2, 13.5+ 0.2, 15.5+ 0.2, 16.9+ 0.2, 19.1+ 0.2, 22.6+ 0.2, 23.3+ 0.2, 24.3+ 0.2, and 26.2+ 0.2.
[0082]
[0032] In some embodiments, disclosed herein is a hydrochloride salt of a compound of the formula:
[0083]
[0084] hydrochloride salt is of the formula:
[0085]
[0086] . In one embodiment, the hydrochloride salt is in crystalline form.
[0087]
[0033] In some embodiments, disclosed herein is a crystalline form of a salt of the formula:
[0088]
[0089] characterized by having an X-ray powder diffraction (XRPD) pattern comprising a peak in degrees at 20 value of 6.8 ± 0.2. In some embodiments, the crystalline salt form (i.e., crystalline Formula III) is characterized by having an X-ray powder diffraction (XRPD) pattern further comprising peaks in degrees at 20 values of 13.9+ 0.2 and 16.5 + 0.2. In some embodiments, the crystalline salt form (i.e., crystalline Formula III) is characterized by having an X-ray powder diffraction (XRPD) pattern having at least one peak in degrees at 20 value selected from 6.8±
[0090]
[0091] 0.2, 8.4± 0.2, 13.9+ 0.2, 14.9+ 0.2, 16.5+ 0.2, 21.6+ 0.2, 22.8+ 0.2, 24.9+ 0.2, and 25.8+ 0.2. In one embodiment, the crystalline salt form (i.e., crystalline Formula III) is characterized by having an X-ray powder diffraction (XRPD) pattern having a peak in degrees at 20 value of 6.8 + 0.2 in combination with at least one peak in degrees at 20 selected from 8.4± 0.2, 13.9± 0.2, 14.9± 0.2, 16.5+ 0.2, 21.6+ 0.2, 22.8+ 0.2, 24.9+ 0.2, and 25.8+ 0.2.
[0092]
[0034] In a further embodiment, disclosed herein is a pharmaceutical composition comprising a disclosed crystalline form of the formula:
[0093]
[0094] and a pharmaceutically acceptable excipient.
[0095]
[0035] In a further embodiment, disclosed herein is a pharmaceutical composition comprising a disclosed crystalline form of the formula:
[0096]
[0097] and a pharmaceutically acceptable excipient.
[0098]
[0036] In a further embodiment, disclosed herein is a pharmaceutical composition comprising a disclosed crystalline form of the formula:
[0099]
[0100] and a pharmaceutically acceptable excipient.
[0101]
[0037] In some embodiments, a disclosed pharmaceutical composition may be a formulation for oral administration.
[0102]
[0038] In an embodiment, disclosed herein is a drug substance comprising at least a detectable amount of a disclosed crystalline form of the formula
[0103]
[0104]
[0039] In another embodiment, disclosed herein is a drug substance comprising a crystalline form of the formula
[0105]
[0106]
[0040] In another embodiment, disclosed herein is a drug substance comprising a crystalline form of the formula
[0107]
[0108] Compositions
[0109]
[0041] The compounds disclosed herein can be formulated for oral administration in forms such as tablets, capsules (each of which includes sustained release or timed release formulations), pellets, pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions. The compounds disclosed herein, such as crystalline Formula I, can also be formulated for intravenous (bolus or in-fusion), intraperitoneal, topical, subcutaneous, intramuscular or transdermal (e.g., patch) administration, all using forms well known to those of ordinary skill in the pharmaceutical arts.
[0110]
[0042] In one embodiment, the disclosure provides pharmaceutical compositions comprising compounds as disclosed herein, such as crystalline Formula I, formulated together with one or more pharmaceutically acceptable excipients. In some embodiments, the present disclosure provides compositions formulated for oral administration. The active ingredient may be compounded, for example, with the usual nontoxic, pharmaceutically acceptable excipients for tablets, pellets, capsules, and any other form suitable for use.
[0111]
[0112] [43J In another embodiment, provided herein are orally administrable, pharmaceutical compositions comprising the compounds disclosed herein, such as crystalline Formula I. In one embodiment, the orally administrable, pharmaceutical compositions are enterically coated. The enterically coated compositions provide at least one of greater bioavailability or reduced stomach upset, when compared to orally administrable, non-enterically coated pharmaceutical compositions. The compositions disclosed herein may be administered to a patient in either a fasted or a fed state. Therefore, in some embodiments, a compound disclosed herein is administered to a subject prior to a meal. In some such embodiments, the compound is administered 3 hours, 2 hours, 1 hour, 30 minutes, or 15 minutes before a meal. In other embodiments, a compound of any embodiments set forth herein is administered to a subject during a meal. In other embodiments, a compound of any of the embodiments described herein is administered to a subject within 3 hours, within 2 hours, within 1 hour, within 30 minutes, or within 1 minutes of a meal.
[0113]
[0044] In one embodiment, provided herein are 1) enterically coated capsules, 2) enterically coated tablets, and 3) enterically coated pellets, wherein each of these comprises the compounds disclosed herein, such as crystalline Formula I, crystalline Formula II, crystalline Formula III.
[0114]
[0045] In one embodiment, the pharmaceutical formulation is an enteric capsule that comprises crystalline Formula I, without an excipient. In one embodiment, the pharmaceutical formulation is an enteric tablet that comprises crystalline Formula I.
[0115]
[0046] In one embodiment, the pharmaceutical formulation is an enteric capsule that comprises crystalline Formula II, without an excipient. In one embodiment, the pharmaceutical formulation is an enteric tablet that comprises crystalline Formula II.
[0116]
[0047] In one embodiment, the pharmaceutical formulation is an enteric capsule that comprises crystalline Formula III, without an excipient. In one embodiment, the pharmaceutical formulation is an enteric tablet that comprises crystalline Formula III.
[0117]
[0048] In some embodiments, the pharmaceutical composition comprising a compound disclosed herein may be filled into capsules that are made from acid resistant materials such as Eudracaps® enteric capsules and Capsugel® Enprotect® capsules. In some embodiments, the pharmaceutical formulation (e.g., enteric capsule) may be administered in a fasted or non-fasted state.
[0118]
[0049] In some embodiments, the enteric capsules comprising a compound disclosed herein may significantly reduce emesis in fasted and non-fasted subjects when compared to HPMC capsules comprising a compound disclosed herein. In some embodiments, the enteric capsules comprising
[0119]
[0120] a compound disclosed herein (e.g., crystalline Formula 1) provide a higher area under the curve (AUG) exposure and much lower variability for the compound disclosed herein (e.g., crystalline Formula I) when compared to HPMC capsules comprising the same compound disclosed herein. In some embodiments, no emesis is observed in the subjects receiving the enteric capsules comprising a compound disclosed herein (e.g., crystalline Formula I). In some embodiments, the subjects dosed with enteric capsules comprising a compound disclosed herein (e.g., crystalline Formula I) show a similar PK profile (e.g., lower drug variability between subjects when same dose is administered) and reduced and / or no emesis regardless of whether the subject is dosed in non-fasted or fasted state.
[0121]
[0050] In some embodiments, the dosing of the enteric capsules with food may help mitigate nausea / vomiting.
[0122]
[0051] In some embodiments, the dosing of the enteric tablets with food may help mitigate nausea / vomiting.
[0123] Enteric Coated Pharmaceutical Compositions
[0124]
[0052] Enteric pharmaceutical formulations are manufactured in such a way that the product passes relatively unchanged through the stomach of the patient, dissolves, and releases the active ingredient when it enters the small intestine. Such formulations have long been used, and may be in capsule, tablet or pellet form. When in tablet or pellet form, the active ingredient is in the inner part of the tablet or pellet and is enclosed in a film or envelope, the “enteric coating”, which is insoluble in acid environments, such as the stomach, but is soluble in near-neutral environments such as the small intestine.
[0125]
[0053] Disclosed herein are orally administrable, pharmaceutical compositions comprising the compounds disclosed herein. In one embodiment, the orally administrable, pharmaceutical compositions are enterically coated. The enterically coated compositions provide at least one of greater bioavailability or reduced stomach upset, when compared to orally administrable, non- enterically coated pharmaceutical compositions. The compositions disclosed herein may be administered to a patient in either a fasted or a fed state.
[0126]
[0054] Disclosed herein are 1) enterically coated capsules, 2) enterically coated tablets, and 3) enterically coated pellets, wherein each of these comprises the compounds disclosed herein, such as crystalline Formula I, crystalline Formula II, crystalline Formula III.
[0127] Enterically coated capsules
[0128]
[0055] Disclosed herein is a dosage form for oral administration. The dosage forms described
[0129]
[0130] herein are composed of a core composition that comprises a compound as disclosed herein (e.g., crystalline Formula I), wherein the compound is contained in a capsule that is sealed and coated with an enteric coating.
[0131]
[0056] In an embodiment, the enterically coated, orally administrable pharmaceutical composition is an enterically coated capsule that comprises: a) a core composition comprising a compound disclosed herein; b) a capsule that contains the core composition, wherein the capsule has a body and a cap; c) a polymeric seal covering the transition between the capsule cap and body; and d) an enteric coating that coats the polymeric seal and capsule.
[0132]
[0057] The enterically coated capsules and tablets release little, if any of the compounds disclosed herein, in fluid having pH < 4.5 (i.e., the stomach) and release the majority of the compound in fluid having pH > 6.0 (i.e., the intestines). In an embodiment, the dosage form releases: none of the compound disclosed herein for up to 2 hours in fluid having pH between 4.5 and 6.0; and the majority of the compound in fluid having pH > 6.0.
[0133]
[0058] In an embodiment, the enteric capsule may be Evonik (Eudracaps® (size 0)), Capsugel (Enprotect® (Size 0)), and CanadaCaps. In one embodiment, the enteric capsule is Eudracaps®. In one embodiment, the enteric capsule is Enprotect®. In one embodiment, the enteric capsule is CanadaCaps.
[0134]
[0059] The enteric coating is made of at least one polymer. In an embodiment, the enteric coating comprises a copolymer. The copolymer may contain at least one of methyl acrylate, methyl methacrylate, methacrylic acid or ethyl acrylate.
[0135]
[0060] According to another embodiment, the enteric coating comprises poly [methacrylic acid, ethyl acrylate] wherein the methacrylic acid and ethyl acrylate are present in a ratio of about 1:1.
[0136]
[0061] According to another embodiment, the enteric coating comprises polymethyl acrylate, methyl methacrylate, methacrylic acid in a ratio of about 7:3:1.
[0137]
[0062] In another embodiment, the core composition further comprises a permeation enhancer that is selected from the group consisting of sodium N-[8- (2 -hydroxybenzoyl) amino] caprylate (SNAC), salcaprozate sodium, sodium caprate (CIO), or 8-(N-2-hydroxy-5-chlorobenzoyl)- amino-caprylic acid (5-CNAC).
[0138]
[0063] According to another embodiment of the present disclosure there is provided a solid oral pharmaceutical dosage form comprising: a) a core composition comprising a compound as disclosed herein and CIO; b) a capsule that contains the core composition and wherein the capsule has a body and a cap; c) a polymeric seal covering the transition between the capsule cap
[0139]
[0140] and body; and d) an enteric coating that coats the polymeric seal and capsule, wherein the coating comprises one or more co-polymers selected from the group consisting of: i) poly [methacrylic acid and ethyl acrylate], wherein the methacrylic acid and ethyl acrylate are present in a ratio of about 1:1; and ii) poly [methyl acrylate, methyl methacrylate, methacrylic acid], wherein the methyl acrylate, methyl methacrylate and methacrylic acid are present in a ratio of about 7:3:1.
[0141]
[0064] In yet another embodiment of the present disclosure there is provided a method of treating a disease or condition in a patient in need thereof comprising administering a dosage form as described herein.
[0142]
[0065] In still another embodiment, there is provided an enteric dosage form of the present disclosure for use in the treatment of a disease or condition in a patient.
[0143]
[0066] According to another embodiment of the present disclosure there is provided a process for preparing a dosage form as described herein, comprising: a) blending all components comprised in the core composition in a suitable blender; b) weighing an amount of the blend formed in step (a) to be the core composition; c) compressing the blend weighed in step (b) using a capsule slug mold; d) placing the slug formed in step (c) into the capsule; e) covering the transition between the capsule cap and body with the polymeric seal; and f) coating the capsule with the enteric coating.
[0144]
[0067] Oral dosage forms that release the disclosed compounds in the middle or distal regions of the intestine provide at least one of higher bioavailability of the therapeutic agent as compared to those that release earlier in the digestive tract, such as the stomach, duodenum or proximal region of small intestine or decreased stomach upset, when compared to an immediate release formulation. Such targeted release may be achieved through the use of the dosage forms described herein.
[0145]
[0068] The dosage forms described herein are able to achieve such targeted release regardless of whether they are administered to the patient in a fed or fasted state. The potential benefits of the availability of such flexible dosing timing and scheduling include improved adherence and efficacy.
[0146]
[0069] Dosage forms designed to target different regions of the intestine were described previously. See, e.g.,Maroni, Alessandra, et al. In vitro and in vivo evaluation of an oral multiple-unit formulation for colonic delivery of insulin. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS 108 (2016): 76-82; Schellekens, R. C. A., et al. Pulsatile drug delivery to ileo-colonic segments by structured incorporation of disintegrants in pH-responsive
[0147]
[0148] polymer coatings. JOURNAL OF CONTROLLED RELEASE 132.2 (2008): 91-98; Liu, Fang, et al. Evolution of a physiological pH 6.8 bicarbonate buffer system: application to the dissolution testing of enteric coated products. European Journal of Pharmaceutics and Biopharmaceutics 78.1 (2011): 151- 157; Maroni, Alessandra, et al. In vitro and in vivo evaluation of an oral multiple-unit formulation for colonic delivery of insulin. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS 108 (2016): 76-82; Schellekens, R. C. A., et al. Pulsatile drug delivery to ileo-colonic segments by structured incorporation of disintegrants in pH- responsive polymer coatings. JOURNAL OF CONTROLLED RELEASE 132.2 (2008): 91-98; Liu, Fang, et al. Evolution of a physiological pH 6.8 bicarbonate buffer system: application to the dissolution testing of enteric coated products. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS 78.1 (2011): 151-157.
[0149]
[0070] The enteric coatings that provide the targeted release characteristics described herein include coatings comprised of one or more polymers or co-polymers. Nonlimiting examples of such polymers or co-polymers include those identified in Table 1 below, where the listed trade names are commercially available products that comprise the polymers or co-polymers indicated, in many cases as aqueous dispersions:
[0150]
[0151] Table 1
[0152] Chemical Name Polymer Example Trade name(s)
[0153] Ratio
[0154] poly[butyl methacrylate. (2- 1 :2:1 Eudragit® E 100, Eudragit® dimethyaminoethyl) methacrylate, E12.5,
[0155] methyl methacrylate Eudragit® E PO
[0156] Polyfethyl acrylate, methyl 2:1 Eudragit® NE 30 D, Eudragit® methacrylate] NE 40 D, Eudragit® NM 30 D Poly [methacrylic acid, methyl 1:1 Eudragit® L 100, Eudragit® L methacrylate] 12.5,
[0157] Eudragit® L 12.5 P Poly[methacrylic acid, ethyl acrylate] 1 :1 Acryl-EZE, Acryl-EZE 93A, Acryl-EZE MP, Eudragit® L30 D- 55, Eudragit® L 100-55, Eastacryl 30 D, Kollicoat® MAE 30 DP, Kollicoat® MAE 100 P Poly [methacrylic acid, methyl 1:2 Eudragit® S 100, Eudragit® S methacrylate] 12.5, Eudragit® S 12.5 P Poly [methyl acrylate, methyl 7:3:1 Eudragit® FS30 D methacrylate, methacrylic acid]
[0158] Poly [ethyl acrylate, methyl l:2:0.2 Eudragit® RL 100, Eudragit® RL methacrylate, trimethylammonioethyl PO, Eudragit® RL 30D, Eudragit® methacrylate chloride] RL 12.5
[0159] Poly [ethyl acrylate, methyl 1:2:0.1 Eudragit® RS 100, Eudragit® RS m eth aery 1 ate, tri m ethyl am monioethyl PO, Eudragit® RS 30 D, methacrylate chloride] Eudragit® RS 12.5 HPMCAS (H) NA
[0160] Hydroxyl propyl methyl cellulose NA
[0161] phthalate (HPMCP)
[0162] Polyvinyl acetate phthalate (PVAP) NA
[0163] Cellulose acetate trimellitate (CAT) NA
[0164] Cellulose acetate phthalate (CAP) NA
[0165]
[0166]
[0167] [71 J In certain embodiments, coatings that may be used in dosage forms of the present disclosure are comprised of one or more of Poly [methacrylic acid, ethyl acrylate] (1:1 ratio) (e.g., Eudragit® L30D-55), Poly [methyl acrylate, methyl methacrylate, methacrylic acid] (7:3: 1 ratio) (e.g., Eudragit® F S30D), Poly [methacrylic acid, methyl methacrylate] (1 :2 ratio) (e.g., Eudragit® S), Poly [methacrylic acid, methyl methacrylate] (1:1 ratio) (e.g., Eudragit® L) and HPMCAS (H). Examples of specific co-polymers include Poly [methacrylic acid, ethyl acrylate] (1:1 ratio) (e.g., Eudragit® L30D-55), Poly [methyl acrylate, methyl methacrylate, methacrylic acid] (7:3: 1 ratio) (e.g., Eudragit® FS30D) and mixtures thereof.
[0168]
[0072] In some embodiments, the coating comprises include between 10 and 70% Poly [methyl acrylate, methyl methacrylate, methacrylic acid] (7:3:1 ratio) (e.g., Eudragit® FS30D). In certain embodiments the coating comprises about 51.6% Poly [methyl acrylate, methyl methacrylate, methacrylic acid] (7:3:1 ratio) (e.g., Eudragit® FS30D). In certain embodiments the coating comprises about 53.3% Poly [methyl acrylate, methyl methacrylate, methacrylic acid] (7:3:1 ratio) (e.g., Eudragit® FS30D).
[0169]
[0073] In certain embodiments the coating comprises a combination of Poly [methacrylic acid, ethyl acrylate] (1:1 ratio) (e.g., Eudragit® L30D-55), Poly[methyl acrylate, methyl methacrylate, methacrylic acid] (7:3:1 ratio) (e.g., Eudragit® FS30D). In certain embodiments the coating comprises a combination of about 13.3 percent Poly [methacrylic acid, ethyl acrylate] (1:1 ratio) (e.g., Eudragit® L30D-55) and about 53.3 percent Poly [methyl acrylate, methyl methacrylate, methacrylic acid] (7:3:1 ratio) (e.g., Eudragit® FS30D). In certain embodiments the coating comprises a combination of about 12.9 percent Poly [methacrylic acid, ethyl acrylate] (1:1 ratio) (e.g., Eudragit® L30D-55) and about 51.6 percent Poly [methyl acrylate, methyl methacrylate, methacrylic acid] (7:3:1 ratio) (e.g., Eudragit® F S30D).
[0170]
[0074] In addition to the composition of the coating, the release profile of the dosage form is also influenced by the amount of coating applied to the sealed capsule, referred to herein as the “coating level.’’ This dimension is expressed herein as the mass of coating per unit area of the capsule, most typically mg / cm2in the context of the dosage forms described herein. In certain embodiments, the coating level is between 5-20 mg / cm2. In certain embodiments, the coating level is between 6-16 mg / cm2. In certain embodiments, the coating level is between 7-10 mg / cm2. In certain embodiments, the coating level is about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15 or about 16 mg / cm2. In certain embodiments the coating level is about 6.5, about 7.5, about 8.5, about 9.5, about 10.2, about 10.5, about 10.9,
[0171]
[0172] about 11.9, about 12.9, about 13.0 or about 13.7 mg / cm2.
[0173]
[0075] The polymer(s) and co-polymer(s) described above are typically provided in the form of aqueous dispersions. A significant component of the enteric coatings described herein therefore is comprised of purified water. In certain embodiments, the water content is between 20-40 percent. In certain embodiments, the water content is about 33 percent.
[0174]
[0076] In some embodiments, the coating includes other excipients that improve the manufacturability and / or function of the coating. An example of such an excipient that may be included is a plasticizer. Commonly used plasticizers include Propylene glycol. Glycerol, Polyethylene glycols (e.g., PEG-400), Glyceryl triacetate (Triacetin), Triethyl citrate (TEC), Acetyl triethyl citrate, Phthalate esters, Diethyl phthalate, Acetylated, Castor oil and Mineral oil. In certain embodiments, the coating comprises TEC. In certain embodiments, the concentration of TEC is from 1-10 percent. In certain embodiments the TEC content is about 3%.
[0175]
[0077] Another excipient that may be included is a pH modifier, which may be used to adjust the pH at which the polymer(s) or co-polymer(s) dissolves. Examples of such pH modifiers are known by those skilled in the art, and include sodium carbonate, sodium bicarbonate, potassium dihydrogen phosphate and ammonium hydroxide.
[0176]
[0078] Another component that may be added as an excipient in the coating composition and / or added to the outside of the coating is a material used to prevent tackiness during storage. An example of such a material is talc.
[0177]
[0079] In addition to the effects of the coatings described above, the release profiles of the dosage forms described herein also result from the use of a sealed capsule. The capsules themselves are hard shelled capsules known in the art, commonly made from natural materials such as gelatin, polysaccharide derivatives, such as carrageenans, or celluloses, such as methylcellulose or hydroxypropyl methylcellulose (HPMC). Capsules are comprised of two pieces: a capsule body that is filled with a core composition and a cap that fits over the body. Selection of a particular capsule for use in the dosage forms described herein is within the skill of persons skilled in the art, and will depend in part on the volume of the core composition to be contained therein. In certain embodiments the capsule is comprised of HPMC.
[0178]
[0080] Capsules are typically soluble in gastrointestinal fluids, so in order to avoid release upstream of the region of the intestine at which release is desired, the capsule must be protected from contact with gastrointestinal fluids before reaching that point. Such protection is provided by using a suitable enteric coating as described above, but in order for the enteric coating to provide
[0179]
[0180] such protection, it must coat the entirety of the capsule, i.e., with no gaps through which fluid may ingress.
[0181]
[0081] It has been found that the addition of a polymeric seal over the edge of the cap of the capsule, where the cap transitions to the body of the capsule, prior to application of the enteric coating helps avoid release in the proximal small intestine and contributes to improved bioavailability. The amount of surface area of the capsule covered by the seal is not critical, as long as it covers the transition from the cap to the body. Thus, the seal may partially or wholly cover the capsule. For example, in certain embodiments the seal may be a thin band around the capsule, and in other embodiments may be a coat or subcoat that covers the entirety of the capsule.
[0182]
[0082] In some embodiments, the polymeric seal is provided through a process known as banding. Banding is typically used on capsule dosage forms filled with liquids to prevent leakage of the liquid interiors, but in the context of the present disclosure, banding serves to prevent external liquid from reaching the capsule’s core composition until the enteric coating has dissolved, as noted above.
[0183]
[0083] Seals for use in dosage form of the present compositions, including bands, may be made from materials having the same dissolution properties as the enteric coating itself, or may have no enteric properties. Seals, including bands, may therefore be made from materials similar to those described above for either the enteric coating or from the same material as the capsule itself. In certain embodiments the band is comprised of the same composition as the enteric coating. In certain embodiments the band is comprised of HPMC. In certain embodiments the band comprises HPMC, ethanol and water. In certain embodiments the band comprises about 17% HPMC, about 58% ethanol and 25% water.
[0184]
[0084] Permeation enhancers increase local permeability (Twarog et al. 2019) and result in increased oral bioavailability for therapeutic use. Examples of permeation enhancers that may be used in the formulations disclosed herein include sodium N-[8-(2 -hydroxybenzoyl) amino] caprylate (SNAC), sodium caprylate (C8), sodium caprate or sodium decanoate (CIO), or 8-(N-2- hydroxy-5-chlorobenzoyl)-amino-caprylic acid (5-CNAC). Salcaprozate sodium has generally regarded as safe (GRAS) status and is contained in FDA-approved medical food (Eligen®- Vitamin Bl 2, Emisphcrc, Roseland, NJ, USA). Rybclsus® tablet, which is approved by FDA, European Medicines Agency and Japan Pharmaceuticals and Medical Devices Agency, contains SNAC at 300 mg. CIO has food additive status with no daily limits on consumption.
[0185]
[0186] [85 J The core compositions of the present disclosure may contain a capsule filler to improve at least one of flow, compactability, tackiness, and density of the blend, in the core. An example of such a material is microcrystalline cellulose (MCC). In certain embodiments, dosage forms of the present disclosure comprise MCC. The core compositions disclosed herein may comprise up to about 80 mg MCC. In certain embodiments, core compositions of the present disclosure comprise no more than about 60 mg MCC.
[0187]
[0086] The composition may include additional functional excipients, such as common tableting / encapsulation excipients. Examples include a lubricant (e.g., magnesium stearate, sodium stearyl fumarate (SFF)), disintegrant (sodium starch glycolate, crospovidone, croscarmellose sodium, starch, etc.) and / or a glidant (colloidal silica, starch, silicone oil, talc, etc.).
[0188]
[0087] An advantage of the dosage forms described herein is that they may achieve acceptable bioavailability regardless of whether they are administered while the patient is in a fed state or a fasted state. When used herein, the term “fed state,” also known as the absorptive state, refers to the condition of a person’s body after they have eaten food and the body is digesting the food and absorbing the nutrients. This condition begins when food is eaten, and may remain for up to about 4 hours depending on the types and amounts of nutrients ingested. The term “fasted state,” by contrast refers to the condition of a person’s body when it is not digesting food and absorbing nutrients. As the duration of the fed state varies, drugs requiring administration during a fasted state are commonly required to be taken in the morning, before breaking the nighttime fast. In certain embodiments, negative food effects on bioavailability are not observed when dosage forms of the present disclosure are co-administered with food. Dosage forms of the present disclosure may be used in the treatment of a range of diseases or disorders.
[0189]
[0088] The dosage forms described herein may also (or alternatively) reduce stomach upset that may be experienced by the patient, compared to when the patient takes a non-enterically coated dosage form.
[0190]
[0089] When used in the treatment of diseases or conditions such as cancer, more specifically, such as cancers susceptible to treatment with a KRAS G12D inhibitor. Examples of such cancers include pancreatic cancer, colorectal cancer and non-small cell lung cancer (NSCLC). The dosage forms disclosed herein may be administered once daily, twice daily, alternate days, every third day, every fourth day, every fifth day, every sixth day or once weekly. Preferably, the dosage forms are administered once daily.
[0191]
[0192] [90J When used herein, the terms “treatment,” “treat,” “treating,” and the like, are meant to include slowing or attenuating the progression of a disease or disorder. These terms also include alleviating, ameliorating, attenuating, eliminating, or reducing one or more symptoms of a disorder or condition, even if the disorder or condition is not actually eliminated and even if progression of the disorder or condition is not itself slowed or reversed.
[0193] Preparing enterically coated capsules
[0194]
[0091] The enterically coated capsules may be prepared by blending a compound disclosed herein, such as crystalline Formula I, and CIO in a suitable blender (at small-scale, all the components are weighed and transferred into ajar and blended for 5 mins at 25 G in a resonant acoustic mixer), weighing the target blend, compressing the blend into a slug using an appropriate capsule slug mold, and placing it to fit inside an enteric capsule body.
[0195]
[0092] The filled capsules are then coated using a pan to different levels of coating expressed in mg / cm2. After coating, each capsule is manually sealed using 10 uL coating solution around cap and body transition area, allowed to dry and then stored refrigerated. The blending conditions, encapsulation / coating / sealing processes are further modified upon scale-up to achieve optimum manufacturability and required capsule attributes depending upon the scale and manufacturing equipment utilized.
[0196] Enteric Tablet
[0197]
[0093] The compounds disclosed herein may be formulated as an enteric tablet. In one embodiment, the tablet comprises a compound as disclosed herein, such as crystalline Formula I, microcrystalline cellulose, croscarmellose sodium, silicon dioxide, hydroxypropyl methyl cellulose, and magnesium stearate. In one embodiment, the enteric tablet contains about 30 wt% to about 50 wt% of a compound disclosed herein. In one embodiment, the tablets further contain titanium dioxide, talc, glyceryl mono and dicaprylcaprate, polyethylene glycol-polyvinyl alcohol graft copolymer, polyvinyl alcohol, and optionally, a coloring agent. The enteric layer is discussed below.
[0198] Enteric Pellet
[0199]
[0094] The compounds disclosed herein may be formulated as an enteric pellet, which is then optionally put into a capsule. The capsule may be enterically coated or not. Thus, in one embodiment, the enterically coated pellets arc contained within a non-cntcrically coated capsule, such as a gelatin capsule.
[0200]
[0095] The enteric pellets comprise a) a core consisting of a compound as disclosed herein (e.g.,
[0201]
[0202] crystalline Formula 1) and one or more pharmaceutically acceptable excipients: b) an optional separating layer; c) an enteric layer comprising hydroxypropyl-methylcellulose acetate succinate (HPMCAS) and a pharmaceutically acceptable excipient; d) an optional finishing layer.
[0203]
[0096] Also disclosed herein is a method of manufacturing an enteric pellet comprising a) providing a core consisting of a compound as disclosed herein (e.g., crystalline Formula I) and one or more pharmaceutically acceptable excipients; b) optionally, applying to the core a separating layer comprising one or more pharmaceutically acceptable excipients; c) applying an enteric layer comprising HPMCAS and one or more pharmaceutically acceptable excipients, wherein the HPMCAS is applied as an aqueous solution or suspension and the application takes place in an apparatus of the fluid bed type; d) optionally, applying a finishing layer.
[0204] The core of the pellet
[0205]
[0097] A core for the pellet is prepared by applying a layer comprising the compounds as disclosed herein (e.g., crystalline Formula I), to an inert core. Such inert cores are conventionally used in pharmaceutical science, and are readily purchased in all industrial countries. In some embodiments, the core is prepared from starch and sucrose, for use in confectionery as well as in pharmaceutical manufacturing. However, cores of any pharmaceutically acceptable excipient may be used, including, for example, microcrystalline cellulose, vegetable gums, waxes, and the like. The primary characteristic of the inert core is to be inert, with regard both to the compounds disclosed herein and the other excipients in the pellet, and with regard to the patient who will ultimately ingest the pellet.
[0206]
[0098] The size of the cores depends, for example, on the desired size of the pellet to be manufactured. In general, pellets can be as small as 0.1 mm, or as large as 2 mm. cores are from about 0.3 to about 0.8 mm, in order to provide finished pellets in the desired size range of from about 0.5 to about 1.5 mm in diameter.
[0207]
[0099] In some embodiments, the cores may be specified as being of particle size ranges such as from 18 to 20 U.S. mesh, from 20 to 25 U.S. mesh, from 25 to 30 U.S. mesh, or from 30 to 35 U.S. mesh to obtain acceptable size distributions of various absolute sizes.
[0208]
[0100] The amount of cores to be used depends on the weights and thicknesses of the added layers; in general, the cores comprise from about 10 to about 70 percent of the product. More preferably, the charge of cores represents from about 15 to about 45 percent of the product.
[0209]
[0101] When manufacture of the pellet begins with inert cores, the compound is coated on the cores to yield a final drug concentration of about 10 to about 25 percent of the product, in
[0210]
[0211] general. The amount of compound, of course, depends on the desired dose of the drug and the quantity of pellets which it is desired to administer.
[0212]
[0102] A convenient manner of coating the cores with compound is the “powder coating” process where the cores are moistened with a sticky liquid or binder, compound is added as a powder, and the mixture is dried. Such a process is regularly carried out in the practice of industrial pharmacy, and suitable equipment is in daily use. Such equipment is, in fact, used in several steps of the present process, and it will, accordingly, be discussed here. Historically, this process has been conducted in conventional coating pans similar to those employed in sugar coating processes. This process can be used to prepare pellets, but this equipment has less efficient air flow and drying capabilities which limits application rates and can result in longer processing times in order to minimize agglomerations.
[0213]
[0103] Alternately, the present product could be made in fluidized bed equipment (using a rotary processor), or in rotating plate equipment such as the Freund CF-Granulator (Vector Corporation, Marion, Iowa). The rotating plate equipment typically consists of a cylinder, the bottom of which is a rotatable plate. Motion of the mass of particles to be coated is provided by friction of the mass between the stationary wall of the cylinder and the rotating bottom of it. Means can be provided to apply warm air to dry the mass, and liquids can be sprayed on the mass and balanced against the drying rate as in the fluidized bed case.
[0214]
[0104] When a powder coating is to be applied, the mass of pellets, in the present case, is maintained in a sticky state, and the powder to be adhered to them, compound in this case, is added continuously or periodically and adheres to the sticky pellets. When all of the compound has been applied, the spray is stopped and the mass is allowed to dry in the air stream. It may be appropriate or convenient to add some inert powders to the compound.
[0215]
[0105] Additional solids may be added to the layer with compound. These solids may be added to facilitate the coating process as needed to aid flow, reduce static charge, aid bulk buildup and form a smooth surface. Inert substances such as talc, kaolin, and titanium dioxide, lubricants such as magnesium stearate, finely divided silicon dioxide, crospovidone, and non-reducing sugars, e.g., sucrose, may be used. The amounts of such substances are in the range from about a few tenths of 1% of the product, up to about 20% of the product. Such solids should be of fine particle size, less than 50 pm, to produce a smooth surface.
[0216]
[0106] The compound is made to adhere to the cores by spraying a pharmaceutical excipient which is sticky and adherent when it is wet, and dries to a strong, coherent film. Pharmaceutical
[0217]
[0218] scientists are aware of and conventionally use many such substances, most of them polymers, such polymers include hydroxypropylmethylcellulose, hydroxypropyl-cellulose and polyvinylpyrrolidone. Additional such substances include methylcellulose, carboxymethylcellulose, acacia and gelatin, for example. The amount of the adhering excipient is in the range from about 4% to about 12% of the product, and depends in large part on the amount of compound to be adhered to the core.
[0219]
[0107] Compound may also be built up on the cores by spraying a slurry comprising compound suspended in a solution of the excipients of the compound layer, dissolved or suspended in sufficient water to make the slurry sprayable. Such a slurry may be milled through a machine adapted for grinding suspensions in order to reduce the particle size of compound. Grinding in suspension form is desirable because it avoids dust generation and containment problems which arise in grinding dry powder drags. A method for applying this suspension is in the classic pharmaceutical fluidized bed coating device, such as the Wurster column, which consists simply of a vertical cylinder with an air-permeable bottom and an upward spraying nozzle close above the bottom, or a downward- spraying nozzle mounted above the product mass. The cylinder is charged with particles to be coated, sufficient volume of air is drawn through the bottom of the cylinder to suspend the mass of particles, and the liquid to be applied is sprayed onto the mass. The temperature of the fluidizing air is balanced against the spray rate to maintain the mass of pellets or tablets at the desired level of moisture and stickiness while the coating is built up.
[0220]
[0108] On the other hand, the core may comprise a monolithic particle in which the compound is incorporated. Such cores may be prepared by the granulation techniques which are wide spread in pharmaceutical science, particularly in the preparation of granular material for compressed tablets. The particle size of the cores is too small for preparation by compression techniques, but the cores may be prepared by mixing the compound into a mass of pharmaceutical excipients, moistening the mass with water or a solvent, drying, and breaking the mass into sized particles in the same size range as described above for the inert cores. This can be accomplished via the process of extrusion and maramerization.
[0221]
[0109] The core for the pellet can also be prepared by mixing compound with conventional pharmaceutical ingredients to obtain the desired concentration and forming the mixture into cores of the desired size by conventional procedures or by the process.
[0222] Separating Layer
[0223]
[0110] The separating layer between the compound-containing core and the enteric layer is not
[0224]
[0225] required, but is a feature of the formulation. The separating layer, if required, provides a smooth base for the application of the enteric layer, to prolong the pellet's resistance to acid conditions, and to improve stability by inhibiting any interaction between the drug and the enteric polymer in the enteric layer.
[0226]
[0111] The smoothing function of the separating layer is purely mechanical, the objective of which is to improve the coverage of the enteric layer and to avoid thin spots in it, caused by bumps and irregularities on the core. Accordingly, the more smooth and free of irregularities the core can be made, the less material is needed in the separating layer, and the need for the smoothing characteristic of the separating layer may be avoided entirely when the compound is of extremely tine particle size and the core is made as close as possible to truly spherical.
[0227]
[0112] In general, the separating layer is composed of coherent or polymeric materials, and finely powdered solid excipients which constitute fillers. When a sugar is used in the separating layer, it is applied in the form of an aqueous solution and constitutes part of or the whole of the coherent material which sticks the separating layer together. In addition to or instead of the sugar, a polymeric material may also be used in the separating layer. For example, substances such as hydroxypropylmethylcellulose, polyvinylpyrrolidone, hydroxypropylcellulose and the like may be used in small amounts to increase the adherence and coherence of the separating layer.
[0228]
[0113] It is further advisable to use a filler excipient in the separating layer to increase the smoothness and solidity of the layer. Substances such as finely powdered talc, silicon dioxide and the like are universally accepted as pharmaceutical excipients and may be added as is convenient in the circumstances to fill and smooth the separating layer.
[0229]
[0114] In general, the amount of sugar in the separating layer may be in the range of from about 2% to about 10% of the product, when a sugar is used at all, and the amount of polymeric or other sticky material may be in the range of from about 0.1 to about 5%. The amount of filler, such as talc, should be in the range of from about 5 to about 15%, based on final product weight.
[0230]
[0115] The separating layer may be applied by spraying aqueous solutions of the sugar or polymeric material, and dusting in the filler as has been described in the preparation of a compound layer. The smoothness and homogeneity of the separating layer can be improved, however, if the filler is thoroughly dispersed as a suspension in the solution of sugar and / or polymeric material, and the suspension is sprayed on the core and dried, using equipment as described above in the preparation of cores with compound layers.
[0231] Enteric Layer
[0232]
[0233] [116J I'he enteric layer is comprised of an enteric polymer, which must be chosen for compatibility with compound as discussed above. The polymer must be one having only a small number of carboxylic acid groups per unit weight or repeating unit of the polymer. In one embodiment, the enteric polymer is hydroxypropylmethylcellulose acetate succinate (HPMCAS), which product is defined as containing not less than 4% and not more than 28% of succinoyl groups, which are the only free carboxylic groups in the compound. See Japanese Standards of Pharmaceutical Ingredients 1991, page 1216-21, Standard No. 19026. HPMCAS is available from Shin-Etsu Chemical Co., Ltd., Tokyo, Japan, under the trademark AQOAT. It is available in two particle size grades and three molecular weight ranges. The L grade, having number average molecular weight of 93,000, is used in the present examples but other grades are expected to be usable.
[0234]
[0117] Enteric polymers may be applied as coatings from aqueous suspensions, from solutions in aqueous or organic solvents, or as a powder. Application from organic solvents is presently not at all favored in the pharmaceutical industry, because of the cost of the solvent and the difficulty in either disposing of solvent vapors or recovering the evaporated solvent. Accordingly, no detailed discussion of application of the enteric layer from organic solvents will be given here, but the pharmaceutical scientist will recognize that such application is entirely possible if circumstances favor it.
[0235]
[0118] The enteric polymer can also be applied according to a method described by Shin-Etsu Chemical Co. Ltd. (Obara, et al., Poster PT6115, AAPS Annual Meeting, Seattle, Wash., Oct. 27-31, 1996). When the enteric polymer is applied as a powder the enteric polymer is added directly in the solid state to the tablets or pellets while plasticizer is sprayed onto the tablets or pellets simultaneously. The deposit of solid enteric particles is then turned into a film by curing. The curing is done by spraying the coated tablets or pellets with a small amount of water and then heating the tablets or pellets for a short time. This method of enteric coating application can be performed employing the same type of equipment as described above in the preparation of cores with compound layers.
[0236]
[0119] When the enteric polymer is applied as an aqueous suspension, a problem in obtaining a uniform, coherent film often results. It is very advisable, accordingly, to purchase a fine particle grade or grind the particles of polymer to an extremely small size before application. It is possible either to grind the dry polymer, as in an air-impaction mill or to prepare the suspension and grind the polymer in slurry form. Slurry grinding is generally preferable, particularly since it
[0237]
[0238] can be used also to grind the filler portion of the enteric layer in the same step. It is advisable to reduce the average particle size of the enteric polymer to the range from about 1 pm to about 5 m, preferably no larger than 3 pm.
[0239]
[0120] When the enteric polymer is applied in the form of a suspension, it is important to assure that the suspension remains homogeneous, and that conditions which favor the agglomeration of the polymer do not occur. Such precautions include maintaining the suspension in a gently stirred condition, but not stirring so vigorously as to create foam, and assuring that the suspension does not stand still in eddies in nozzle bodies, for example, or in over-large delivery tubing.
[0240] Frequently polymers in suspension form will agglomerate if the suspension becomes too warm, and the critical temperature may be as low as 30° C. in individual cases. Since spray nozzles and tubing are exposed to hot air in the usual fluid bed type equipment, care must be taken to assure that the suspension is kept moving briskly through the equipment to cool the tubing and nozzle. When HPMCAS is used, in particular, it is advisable to cool the suspension below 20° C. before application, to cool the tubing and nozzle by pumping a little cold water through them before beginning to pump the suspension, and to use supply tubing with as small a diameter as the spray rate will allow so that the suspension can be kept moving rapidly in the tubing.
[0241]
[0121] It is in the present disclosure, however, to apply the enteric polymer as an aqueous solution whenever it is possible to do so. In the case of HPMCAS, dissolution of the polymer can be obtained by neutralizing the polymer, preferably with ammonia. Neutralization of the polymer may be obtained merely by adding ammonia, preferably in the form of aqueous ammonium hydroxide to a suspension of the polymer in water; complete neutralization results in complete dissolution of the polymer at about pH 5.7-5.9. Good results are also obtained when the polymer is partially neutralized, by adding less than the equivalent amount of ammonia. In such case, the polymer which has not been neutralized remains in suspended form, suspended in a solution of neutralized polymer. As noted earlier, it is obviously important to control the particle size of the polymer when such a process is to be used. Use of neutralized polymer more readily provides a smooth, coherent enteric layer than when a suspended polymer is used, and use of partially neutralized polymer provides intermediate degrees of smoothness and coherency. Particularly when the enteric layer is applied over a very smooth separating layer, excellent results may be obtained from partially neutralized enteric polymer.
[0242]
[0122] The extent of neutralization may be varied over a range without adversely affecting results or ease of operation. For example, operation with from about 25% to about 100% neutralization
[0243]
[0244] is in the present disclosure. Another condition is from about 45% to about 100% neutralization, and another condition is from about 65% to about 100%. Still another manner of neutralization is from about 25% to about 65% neutralized. It is found, however, that the enteric polymer in the resulting product, after drying, is neutralized to a lesser extent than when applied. When neutralized or partially neutralized HPMCAS is applied, the HPMCAS in the final product is from about 0% to about 25% neutralized, more preferably from about 0% to about 15% neutralized.
[0245]
[0123] Most enteric polymers require the addition of a plasticizer for best results. In the case of HPMCAS, the plasticizer is triethyl citrate, used in an amount up to about 15 %-30% of the amount of enteric polymer in aqueous suspension application. When a neutralized HPMCAS is employed, lower levels or no plasticizer may be required.
[0246]
[0124] Minor ingredients, such as antifoam, suspending agents when the polymer is in suspended form, and surfactants to assist in smoothing the film are also commonly used. For example, silicone anti-foams, surfactants such as polysorbate 80, sodium lauryl sulfate and the like and suspending agents such as carboxymethylcellulose, vegetable gums and the like may commonly be used at amounts in the general range up to 1% of the product.
[0247]
[0125] Usually, an enteric layer is filled with a powdered excipient such as talc, glyceryl monostearate or hydrated silicon dioxide to build up the thickness of the layer, to strengthen it, to reduce static charge, and to reduce particle cohesion. Amounts of such solids in the range of from about 1% to about 10% of the final product may be added to the enteric polymer mixture, while the amount of enteric polymer itself is usually in the range from about 5% to about 25%, more preferably, from about 10% to about 20%.
[0248]
[0126] Application of the enteric layer to the pellets follows the same general procedure previously discussed, using fluid bed type equipment with simultaneous spraying of enteric polymer solution or suspension and warm air drying. Temperature of the drying air and the temperature of the circulating mass of pellets should be kept in the ranges advised by the manufacturer of the enteric polymer.
[0249] Finishing Layer
[0250]
[0127] A finishing layer over the enteric layer is not always necessary, but it frequently improves the elegance of the product and its handling, storage and machinability and may provide further benefits as well. The simplest finishing layer is simply a small amount, about less than 1% of an anti-static ingredient such as talc or silicon dioxide, simply dusted on the surface of the pellets.
[0251]
[0252] Another simple finishing layer is a small amount, about 1%, of a wax such as beeswax melted onto the circulating mass of pellets to further smooth the pellets, reduce static charge, prevent any tendency for pellets to stick together, and increase the hydrophobicity of the surface.
[0253]
[0128] More complex finishing layers may constitute a final sprayed-on layer of ingredients. For example, a thin layer of polymeric material such as hydroxypropylmethylcellulose, polyvinylpyrrolidone and the like, in an amount such as from about 2% up to about 10%, may be applied. The polymeric material may also carry a suspension of an opacifier, a bulking agent such as talc, or a coloring material, particularly an opaque finely divided color agent such as red or yellow iron oxide. Such a layer quickly dissolves away in the stomach, leaving the enteric layer to protect the compound, but provides an added measure of pharmaceutical elegance and protection from mechanical damage to the product.
[0254]
[0129] Finishing layers to be applied to the present product are of essentially the same types commonly used in pharmaceutical science to smooth, seal and color enteric products, and may be formulated and applied in the usual manners.
[0255] Therapeutic uses
[0256]
[0130] Also provided herein are therapies including a compound disclosed herein (e.g., crystalline Formula I, crystalline Formula II, crystalline Formula III), for the treatment of patients with a disease, such as cancer. The compound disclosed herein may be used in monotherapy or in combination with one or more additional therapeutic agents. The therapies may provide new treatment options for patients, and may provide an enhanced beneficial therapeutic effect in some patients over known therapies.
[0257]
[0131] The efficacy of a cancer treatment can be measured by various endpoints commonly used in evaluating cancer treatments, including but not limited to tumor regression, tumor weight or size shrinkage, time to progression, overall survival, progression free survival, overall response rate, duration of response, best overall response, disease control rate, clinical benefit rate, time to response, and quality of life.
[0258]
[0132] In some embodiments, provided herein are methods of treating cancer, comprising administering to a patient in need thereof, an effective amount of a compound disclosed herein. In this method, the cancer can be lung cancer, colorectal cancer, pancreatic cancer, bladder cancer, cervical cancer, endometrial cancer, ovarian cancer, biliary tract carcinoma (preferably cholangiocarcinoma), multiple myeloma, gastric, or esophageal cancer. In this method, the cancer
[0259]
[0260] can more specifically be non-small cell lung cancer, pancreatic cancer, or colorectal cancer. In an embodiment the cancer can be non-small cell lung cancer. In an embodiment, the cancer can be pancreatic cancer. In an embodiment, the cancer can be colorectal cancer.
[0261]
[0133] Also provided herein is a method of treating cancer, comprising administering to a patient in need thereof, an effective amount of a compound disclosed herein, in which the cancer has one or more cells that express a mutant KRAS G12A, G12C, G12D, G12S, G12V and / or G13D protein. In some embodiments, the cancer has one or more cells that express a mutant KRAS G12C, G12D, and / or G12V protein. In this method, the cancer can be non-small cell lung cancer, pancreatic cancer, or colorectal cancer, in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein. In an embodiment, the cancer is non-small cell lung carcinoma in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein. In an embodiment, the cancer is mutant pancreatic cancer in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein. In an embodiment, the cancer is colorectal carcinoma in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein. This method also includes treating KRAS G12C, G12D, and / or G12V mutant bearing cancers of other origins.
[0262]
[0134] Further provided herein is a method of treating a patient with a cancer that has a KRAS G12A, G12C, G12D, G12S, G12V and / or G13D mutation comprising administering to a patient in need thereof an effective amount of a compound disclosed herein, such as crystalline Formula I, crystalline Formula II, crystalline Formula III.
[0263]
[0135] In one embodiment, the cancer that has a KRAS G12C, G12D, and / or G12V mutation can be KRAS G12C, G12D, and / or G12V mutant lung cancer, KRAS G12C, G12D, and / or G12V mutant pancreatic cancer, KRAS G12C, G12D, and / or G12V mutant cervical cancer, KRAS G12C, G12D, and / or G12V mutant esophageal cancer, KRas G12C, G12D, and / or G12V mutant endometrial cancer, KRAS G12C, G12D, and / or G12V mutant ovarian cancer, KRAS G12C, G12D, and / or G12V mutant cholangiocarcinoma, and KRAS G12C, G12D, and / or G12V mutant colorectal cancer. In an embodiment the cancer that has a KRAS G12C, G12D, and / or G12V mutation can be KRAS G12C, G12D, and / or G12V mutant non-small cell lung cancer. In an embodiment the cancer that has a KRAS G12C, G12D, and / or G12V mutation can be KRAS G12C, G12D, and / or G12V mutant pancreatic cancer. In an embodiment the cancer that has a KRAS G12C, G12D, and / or G12V mutation can be KRAS G12C, G12D, and / or G12V mutant colorectal cancer.
[0264]
[0265] [136J Additionally provided herein is a method of modulating a mutant G12A, G12C, G12D, G12S, G12V and / or G13D enzyme in a patient in need thereof, by administering a compound disclosed herein. In one embodiment this method comprises inhibiting a human mutant G12A, G12C, G12D, G12S, G12V and / or G13D enzyme.
[0266]
[0137] Further provided herein is a compound disclosed herein for use in therapy. The compound or a pharmaceutically acceptable salt thereof, can be for use in treating cancer. For this use in treating cancer, the cancer can be lung cancer, colorectal cancer, pancreatic cancer, bladder cancer, cervical cancer, endometrial cancer, ovarian cancer, biliary tract carcinoma (preferably cholangiocarcinoma), multiple myeloma, or esophageal cancer. The cancer can more specifically be non-small cell lung cancer, pancreatic cancer, or colorectal cancer. In an embodiment, the cancer is non-small cell lung cancer. In an embodiment, the cancer is pancreatic cancer. In an embodiment, the cancer is colorectal cancer. The cancer can have one or more cancer cells that express the mutant KRAS G12C, G12D, and / or G12V protein such as KRAS G12C, G12D, and / or G12V mutant lung cancer, KRAS G12C, G12D, and / or G12V mutant pancreatic cancer, KRAS G12C, G12D, and / orG12V mutant cervical cancer, KRAS G12C, G12D, and / or G12V mutant esophageal cancer, KRAS G12C, G12D, and / or G12V mutant endometrial cancer, KRAS G12C, G12D, and / or G12V mutant ovarian cancer, KRAS G12C, G12D, and / or G12V mutant cholangiocarcinoma, and KRAS G12C, G12D, and / or G12V mutant colorectal cancer. In these uses, the cancer is selected from: KRAS G12C, G12D, and / or G12V mutant non-small cell lung cancer, KRAS G12C, G12D, and / or G12V mutant colorectal cancer, and KRAS G12C, G12D, and / or G12V mutant pancreatic cancer. Additionally, the cancer can be non-small cell lung cancer, and one or more cells express KRAS G12C, G12D, and / or G12V mutant protein. Further, the cancer can be colorectal cancer, and one or more cells express KRAS G12C, G12D, and / or G12V mutant protein. Additionally, the cancer can be pancreatic cancer, and one or more cells express KRAS G12C, G12D, and / or G12V mutant protein. The patient can have a cancer that was determined to have one or more cells expressing the KRAS G12C, G12D, and / or G12V mutant protein prior to administration of the compound or a pharmaceutically acceptable salt thereof. The patient may have been treated with a different course of treatment prior to being treated as described herein.
[0267]
[0138] The compounds disclosed herein may also be used in the manufacture of a medicament for treating cancer. When used in the manufacture of a medicament, the cancer can be lung cancer, colorectal cancer, pancreatic cancer, bladder cancer, cervical cancer, endometrial cancer, ovarian cancer, biliary tract carcinoma (preferably cholangiocarcinoma), multiple myeloma, or esophageal
[0268]
[0269] cancer. The cancer can more specifically be non-small cell lung cancer, pancreatic cancer, or colorectal cancer. In an embodiment, the cancer is non-small cell lung cancer. In an embodiment, the cancer is pancreatic cancer. In an embodiment, the cancer is colorectal cancer. The cancer can have one or more cancer cells that express the mutant KRAS G12A, G12C, G12D, G12S, G12V and / or G13D protein. In one embodiment, the cancer can have one or more cancer cells that express the mutant KRAS G12C, G12D, and / or G12V protein. When the cancer cells express KRAS G12C, G12D, and / or G12V protein, the cancer can be selected from KRAS G12C, G12D, and / or G12V mutant non-small cell lung cancer, KRAS G12C, G12D, and / or G12V mutant colorectal cancer, and KRAS G12C, G12D, and / or G12V mutant pancreatic cancer.
[0270]
[0139] Also provided herein is a method of treating cancer, comprising administering to a patient in need thereof, an effective amount of a compound disclosed herein (e.g., crystalline Formula I, crystalline Formula II, crystalline Formula III), and one or more of a PD-1 inhibitor, a PD-L1 inhibitor, a CDK4 / CDK6 inhibitor, an EGFR inhibitor, an ERK inhibitor, an Aurora A inhibitor, a SHP2 inhibitor, a platinum agent, and pemetrexed, or pharmaceutically acceptable salts thereof, in which the cancer has one or more cells that express a mutant KRAS G12A, G12C, G12D, G12S, G12V and / or G13D protein. In some embodiments, the compound disclosed herein is for use in simultaneous, separate, or sequential combination with one or more of a PD-1 or PD-L1 inhibitor, a CDK4 / CDK6 inhibitor, an EGFR inhibitor, an ERK inhibitor, an Aurora A inhibitor, a SHP2 inhibitor, a platinum agent, and pemetrexed, or pharmaceutically acceptable salts thereof, in the treatment of cancer. Additionally provided is a combination comprising a compound disclosed herein, and one or more of a PD- 1 or PD-L1 inhibitor, a CDK4 / CDK6 inhibitor, an EGFR inhibitor, an ERK inhibitor, an Aurora A inhibitor, a SHP2 inhibitor, a platinum agent, and pemetrexed, or pharmaceutically acceptable salts thereof, for simultaneous, separate, or sequential use in the treatment of cancer.
[0271]
[0140] Also provided is a method of treating cancer, comprising administering to a patient in need thereof, an effective amount of a compound disclosed herein, and a PD-1 or PD-L1 inhibitor, in which the cancer has one or more cells that express a mutant KRAS G12A, G12C, G12D, G12S, G12V and / or G13D protein. In some embodiments, the compound disclosed herein is for use in simultaneous, separate, or sequential combination with a PD- 1 or PD-L1 inhibitor, for use in the treatment of cancer. Additionally provided is a combination comprising a compound disclosed herein, and a PD-1 or PD-L1 inhibitor, for simultaneous, separate, or sequential use in the treatment of cancer. As used herein, the PD-1 or PD-L1 inhibitor can be pembrolizumab; the PD-1 or PD-
[0272]
[0273] L1 inhibitor can be nivolumab; the PD-1 or PD-L1 inhibitor can be cemiplimab; the PD-1 or PD- L1 inhibitor can be sintilimab; the PD-1 or PD-L1 inhibitor can be atezolizumab; the PD-1 or PD- L1 inhibitor can be avelumab; the PD-1 or PD-L1 inhibitor can be durvalumab; or the PD-1 or PD- L1 inhibitor can be lodapilimab. As described herein, the cancer can be non-small cell lung carcinoma, in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein; the cancer can be colorectal carcinoma in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein; or the cancer can be mutant pancreatic cancer in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein. This method also includes treating KRAS G12C, G12D, and / or G12V mutant bearing cancers of other origins.
[0274]
[0141] Also provided is a method of treating cancer, comprising administering to a patient in need thereof, an effective amount of a compound disclosed herein, and a CDK4 / CDK6 inhibitor, or a pharmaceutically acceptable salt thereof, in which the cancer has one or more cells that express a mutant KRAS G12A, G12C, G12D, G12S, G12V and / or G13D protein. Further provided is a compound disclosed herein, for use in simultaneous, separate, or sequential combination with a CDK4 / CDK6 inhibitor, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer, in which the cancer has one or more cells that express a mutant KRAS G 12C, G 12D, and / or G12V protein. Additionally provided is a combination comprising a compound disclosed herein, and a CDK4 / CDK6 inhibitor, or a pharmaceutically acceptable salt thereof, for simultaneous, separate, or sequential use in the treatment of cancer, in which the cancer has one or more cells that express a mutant KRAS G12A, G12C, G12D, G12S, G12V and / or G13D protein. As used herein, the CDK4 / CDK6 inhibitor can be abemaciclib; the CDK4 / CDK6 inhibitor can be palbociclib; or the CDK4 / CDK6 inhibitor can be ribociclib. As described herein, the cancer can be non-small cell lung carcinoma, in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein; the cancer can be colorectal carcinoma in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein; the cancer can be mutant pancreatic cancer in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein. This method also includes treating KRAS G12C, G12D, and / or G12V mutant bearing cancers of other origins.
[0275]
[0142] Also provided is a method of treating cancer, comprising administering to a patient in need thereof, an effective amount of a compound disclosed herein, and an EGFR inhibitor, or a pharmaceutically acceptable salt thereof, in which the cancer has one or more cells that express a
[0276]
[0277] mutant KRAS G12A, G12C, G12D, G12S, G12V and / or G13D protein. Further provided is a compound disclosed herein, for use in simultaneous, separate, or sequential combination with an EGFR inhibitor, or a pharmaceutically acceptable salt thereof, for the treatment of cancer. Additional provided is a combination comprising a compound disclosed herein, and an EGFR inhibitor, or a pharmaceutically acceptable salt thereof, for simultaneous, separate, or sequential use in the treatment of cancer. As used herein, the EGFR inhibitor can be erlotinib; the EGFR inhibitor can be afatinib; the EGFR inhibitor can be gefitinib; the EGFR inhibitor can be cetuximab. As described herein, the cancer can be non-small cell lung carcinoma, in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein; the cancer can be colorectal carcinoma in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein; or the cancer can be mutant pancreatic cancer in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein. This method also includes treating KRAS G12A, G12C, G12D, G12S, G12V and / or G13D mutant bearing cancers of other origins.
[0278]
[0143] Also provided is a method of treating cancer, comprising administering to a patient in need thereof, an effective amount of a compound disclosed herein, and an ERK inhibitor, or a pharmaceutically acceptable salt thereof, in which the cancer has one or more cells that express a mutant KRAS G12A, G12C, G12D, G12S, G12V and / or G13D protein. Also provided is a method of treating cancer, comprising administering to a patient in need thereof, an effective amount of a compound disclosed herein, and an Aurora A inhibitor, in which the cancer has one or more cells that express a mutant KRAS G12A, G12C, G12D, G12S, G12V and / or G13D protein. Further provided is a compound disclosed herein, for use in simultaneous, separate, or sequential combination with an Aurora A inhibitor, or a pharmaceutically acceptable salt thereof, for the treatment of cancer, in which the cancer has one or more cells that express a KRAS G12A, G12C, G12D, G12S, G12V and / or G13D protein. Further provided is a compound disclosed herein, for use in simultaneous, separate, or sequential combination with an ERK inhibitor, or a pharmaceutically acceptable salt thereof, for the treatment of cancer, in which the cancer has one or more cells that express a mutant KRAS G12A, G12C, G12D, G12S, G12V and / or G13D protein. Additionally provided is a combination comprising a compound disclosed herein, and an ERK inhibitor, or a pharmaceutically acceptable salt thereof, for simultaneous, separate, or sequential use in the treatment of cancer. As used herein, the ERK inhibitor can be LY3214996; the ERK inhibitor can be LTT462; or the ERK inhibitor can be KO-947. As described herein, the cancer can
[0279]
[0280] be non-small cell lung carcinoma, in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein; the cancer can be colorectal carcinoma in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein; the cancer can be mutant pancreatic cancer in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein. This method also includes treating KRAS G12A, G12C, G12D, G12S, G12V and / or G13D mutant bearing cancers of other origins.
[0281]
[0144] Also provided is a method of treating cancer, comprising administering to a patient in need thereof, an effective amount of a compound disclosed herein, and an Aurora A inhibitor, in which the cancer has one or more cells that express a mutant G12A, G12C, G12D, G12S, G12V and / or G13D protein. Further provided is a compound disclosed herein, or a pharmaceutically acceptable salt thereof, for use in simultaneous, separate, or sequential combination with an Aurora A inhibitor, or a pharmaceutically acceptable salt thereof, for the treatment of cancer, in which the cancer has one or more cells that express a mutant G12A, G12C, G12D, G12S, G12V and / or G13D protein. Additionally provided is a combination comprising a compound disclosed herein, and an Aurora A inhibitor, for simultaneous, separate, or sequential use in the treatment of cancer. As used herein, the Aurora A inhibitor can be alisertib, tozasertib, (2R,4R)-l-[(3-chloro-2-fluoro-phenyl)methyl]-4-[[3-fluoro-6-[(5-methyl-lH-pyrazol-3-yl)amino]-2-pyridyl]methyl]-2-methyl- piperidine-4-carboxylic acid, (2R,4R)-l-[(3-chloro-2-fluoro-phenyl)methyl]-4-[[3-fluoro-6-[(5- methyl-lH-pyrazol-3-yl)amino]-2-pyridyl]methyl]-2-methyl-piperidine-4-carboxylic acid : 2- methylpropan-2-amine (1:1) salt, and (2R,4R)-l-[(3-chloro-2-fluoro-phenyl)methyl]-4-[[3-fluoro- 6-[(5-methyl-lH-pyrazol-3-yl)amino]-2-pyridyl]methyl]-2-methyl-piperidine-4-carboxylic acid : amine (1:1) salt, or a pharmaceutically acceptable salt thereof. In one embodiment, the Aurora A inhibitor is (2R,4R)-l-[(3-chloro-2-fluoro-phenyl)methyl]-4-[[3-fluoro-6-[(5-methyl-lH-pyrazol- 3-yl)amino]-2-pyridyl]methyl]-2-methyl-piperidine-4-carboxylic acid. As described herein, the cancer can be non-small cell lung carcinoma, in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein; the cancer can be colorectal carcinoma in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein; the cancer can be mutant pancreatic cancer in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein. This method also includes treating KRAS G12A, G12C, G12D, G12S, G12V and / or G13D mutant bearing cancers of other origins.
[0282]
[0145] Also provided is a method of treating cancer, comprising administering to a patient in need thereof, an effective amount of a compound disclosed herein, and a SHP2 inhibitor, in which the
[0283]
[0284] cancerhas one or more cells that express a mutant KRAS G12A, G12C, G12D, G12S, G12V and / or G13D protein. Further provided is a compound disclosed herein, for use in simultaneous, separate, or sequential combination with a SHP2 inhibitor, or a pharmaceutically acceptable salt thereof, for the treatment of cancer, in which the cancer has one or more cells that express a mutant KRAS G12A, G12C, G12D, G12S, G12V and / or G13D protein. Additionally provided is a combination comprising a compound disclosed herein, and a SHP2 inhibitor, for simultaneous, separate, or sequential use in the treatment of cancer. As used herein, the SHP2 inhibitor, or a pharmaceutically acceptable salt thereof, can be a Type I SIIP2 Inhibitor or a Type II SIIP2 Inhibitor. Examples of Type I SHP2 inhibitors include, but are not limited to, PHPS1, GS-493, NSC-87877, NSC-117199, and Cefsulodin, and pharmaceutically acceptable salts thereof. Examples of Type II SHP2 inhibitors include, but are not limited to, IAB-3068, IAB-3312, RMC-4550, RMC-4630, SHP099, SHP244, SHP389, SHP394, TNO155, RG-6433, and RLY-1971, and pharmaceutically acceptable salts thereof. Additional examples of SHP2 inhibitors include, but are not limited to, BBP-398, IACS-15509, IACS-13909, X37, ERAS-601, SH3809, HBI-2376, ETS-001, and PCC0208023, and pharmaceutically acceptable salts thereof. As described herein, the cancer can be non-small cell lung carcinoma, in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein; the cancer can be colorectal carcinoma in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein; the cancer can be mutant pancreatic cancer in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein. This method also includes treating KRAS G12A, G12C, G12D, G12S, G12V and / or G13D mutant bearing cancers of other origins.
[0285]
[0146] Also provided is a method of treating cancer, comprising administering to a patient in need thereof, an effective amount of a compound disclosed herein, and a platinum agent, in which the cancer has one or more cells that express a mutant KRAS G12A, G12C, G12D, G12S, G12V and / or G13D protein. Further provided is a compound disclosed herein, for use in simultaneous, separate, or sequential combination with a platinum agent, or a pharmaceutically acceptable salt thereof, for the treatment of cancer, in which the cancer has one or more cells that express a mutant KRAS G12A, G12C, G12D, G12S, G12V and / or G13D protein. Additionally provided is a combination comprising a compound disclosed herein, and a platinum agent, for simultaneous, separate, or sequential use in the treatment of cancer. As used herein, the platinum agent can be cisplatin; the platinum agent can be carboplatin; or the platinum agent can be oxaliplatin. As described herein, the cancer can be non-small cell lung carcinoma, in which the cancer has one or more cells that
[0286]
[0287] express a KRAS G12C, G12D, and / or G12V mutant protein; the cancer can be colorectal carcinoma in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein; the cancer can be mutant pancreatic cancer in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein. This method also includes treating KRAS G12A, G12C, G12D, G12S, G12V and / or G13D mutant bearing cancers of other origins.
[0288]
[0147] Also provided is a method of treating cancer, comprising administering to a patient in need thereof, an effective amount of a compound disclosed herein, and a folate analog, in which the cancer has one or more cells that express a mutant KRAS G12A, G12C, G12D, G12S, G12V and / or G13D protein. Further provided is a compound disclosed herein, for use in simultaneous, separate, or sequential combination with a folate analog, or a pharmaceutically acceptable salt thereof, for the treatment of cancer, in which the cancer has one or more cells that express a mutant KRAS G12A, G12C, G12D, G12S, G12V and / or G13D protein. Additionally provided is a combination comprising a compound disclosed herein, and a folate analog, for simultaneous, separate, or sequential use in the treatment of cancer. As used herein, the folate analog can be folinic acid (leucovorin). As described herein, the cancer can be non-small cell lung carcinoma, in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein; the cancer can be colorectal carcinoma in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein; the cancer can be mutant pancreatic cancer in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein. This method also includes treating KRAS G12A, G12C, G12D, G12S, G12V and / or G13D mutant bearing cancers of other origins.
[0289]
[0148] Also provided is a method of treating cancer, comprising administering to a patient in need thereof, an effective amount of a compound disclosed herein, and an antimetabolite, in which the cancer has one or more cells that express a mutant KRAS G12A, G12C, G12D, G12S, G12V and / or G13D protein. Further provided is a compound disclosed herein, for use in simultaneous, separate, or sequential combination with an antimetabolite, or a pharmaceutically acceptable salt thereof, for the treatment of cancer, in which the cancer has one or more cells that express a mutant KRAS G12A, G12C, G12D, G12S, G12V and / or G13D protein. Additionally provided is a combination comprising a compound disclosed herein, and an antimetabolite, for simultaneous, separate, or sequential use in the treatment of cancer. As used herein, the antimetabolite can be fluorouracil; the antimetabolite can be gemcitabine. As described herein, the cancer can be non-small cell lung
[0290]
[0291] carcinoma, in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein; the cancer can be colorectal carcinoma in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein; the cancer can be mutant pancreatic cancer in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein. This method also includes treating KRAS G12A, G12C, G12D, G12S, G12V and / or G13D mutant bearing cancers of other origins.
[0292]
[0149] Also provided is a method of treating cancer, comprising administering to a patient in need thereof, an effective amount of a compound disclosed herein, and a taxane, in which the cancer has one or more cells that express a mutant KRAS G12A, G12C, G12D, G12S, G12V and / or G13D protein. Further provided is a compound disclosed herein, for use in simultaneous, separate, or sequential combination with a taxane, or a pharmaceutically acceptable salt thereof, for the treatment of cancer, in which the cancer has one or more cells that express a mutant KRAS G12A, G12C, G12D, G12S, G12V and / or G13D protein. Additionally provided is a combination comprising a compound disclosed herein, and a taxane, for simultaneous, separate, or sequential use in the treatment of cancer. As used herein, the taxane can be paclitaxel. As described herein, the cancer can be non-small cell lung carcinoma, in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein; the cancer can be colorectal carcinoma in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein; the cancer can be mutant pancreatic cancer in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein. This method also includes treating KRAS G12A, G12C, G12D, G12S, G12V and / or G13D mutant bearing cancers of other origins.
[0293]
[0150] Also provided is a method of treating cancer, comprising administering to a patient in need thereof, an effective amount of a compound disclosed herein, and a camptothecin, in which the cancer has one or more cells that express a mutant KRAS G12A, G12C, G12D, G12S, G12V and / or G13D protein. Further provided is a compound disclosed herein, for use in simultaneous, separate, or sequential combination with a camptothecin, or a pharmaceutically acceptable salt thereof, for the treatment of cancer, in which the cancer has one or more cells that express a mutant KRAS G12A, G12C, G12D, G12S, G12V and / or G13D protein. Additionally provided is a combination comprising a compound disclosed herein, and a camptothecin, for simultaneous, separate, or sequential use in the treatment of cancer. As used herein, the camptothecin can be irinotecan. As described herein, the cancer can be non-small cell lung carcinoma, in which the cancer has one or
[0294]
[0295] more cells that express a KRAS G12C, G12D, and / or G12V mutant protein; the cancer can be colorectal carcinoma in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein; the cancer can be mutant pancreatic cancer in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein. This method also includes treating KRAS G12A, G12C, G12D, G12S, G12V and / or G13D mutant bearing cancers of other origins.
[0296]
[0151] Also provided is a method of treating cancer, comprising administering to a patient in need thereof, an effective amount of a compound disclosed herein, and FOLFIRINOX, in which the cancer has one or more cells that express a mutant KRAS G12A, G12C, G12D, G12S, G12V and / or G13D protein. Further provided is a compound disclosed herein, for use in simultaneous, separate, or sequential combination with FOLFIRINOX, or a pharmaceutically acceptable salt thereof, for the treatment of cancer, in which the cancer has one or more cells that express a mutant KRAS G12A, G12C, G12D, G12S, G12V and / or G13D protein. Additionally provided is a combination comprising a compound disclosed herein, and FOLFIRINOX, for simultaneous, separate, or sequential use in the treatment of cancer. As described herein, the cancer can be non-small cell lung carcinoma, in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein; the cancer can be colorectal carcinoma in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein; the cancer can be mutant pancreatic cancer in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein. This method also includes treating KRAS G12A, G12C, G12D, G12S, G12V and / or G13D mutant bearing cancers of other origins.
[0297]
[0152] Also provided is a method of treating cancer, comprising administering to a patient in need thereof, an effective amount of a compound disclosed herein, and FOLFOX, in which the cancer has one or more cells that express a mutant KRAS G12A, G12C, G12D, G12S, G12V and / or G13D protein. Further provided is a compound disclosed herein, for use in simultaneous, separate, or sequential combination with FOLFOX, or a pharmaceutically acceptable salt thereof, for the treatment of cancer, in which the cancer has one or more cells that express a mutant KRAS G12A, G12C, G12D, G12S, G12V and / or G13D protein. Additionally provided is a combination comprising a compound disclosed herein, and FOLFOX, for simultaneous, separate, or sequential use in the treatment of cancer. As described herein, the cancer can be non-small cell lung carcinoma, in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein; the cancer can be colorectal carcinoma in which the cancer has one or more
[0298]
[0299] cells that express a KRAS G12C, G12D, and / or G12V mutant protein; the cancer can be mutant pancreatic cancer in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein. This method also includes treating KRAS G12A, G12C, G12D, G12S, G12V and / or G13D mutant bearing cancers of other origins.
[0300]
[0153] Also provided is a method of treating cancer, comprising administering to a patient in need thereof, an effective amount of a compound disclosed herein, and FOLFIRI, in which the cancer has one or more cells that express a mutant KRAS G12A, G12C, G12D, G12S, G12V and / or G13D protein. Further provided is a compound disclosed herein, for use in simultaneous, separate, or sequential combination with FOLFIRI, or a pharmaceutically acceptable salt thereof, for the treatment of cancer, in which the cancer has one or more cells that express a mutant KRAS G12A, G12C, G12D, G12S, G12V and / or G13D protein. Additionally provided is a combination comprising a compound disclosed herein, and FOLFIRI, for simultaneous, separate, or sequential use in the treatment of cancer. As described herein, the cancer can be non-small cell lung carcinoma, in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein; the cancer can be colorectal carcinoma in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein; the cancer can be mutant pancreatic cancer in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein. This method also includes treating KRAS G12A, G12C, G12D, G12S, G12V and / or G13D mutant bearing cancers of other origins.
[0301]
[0154] Also provided is a method of treating cancer, comprising administering to a patient in need thereof, an effective amount of a compound a compound disclosed herein, and pemetrexed, in which the cancer has one or more cells that express a mutant KRAS G12A, G12C, G12D, G12S, G12V and / or G13D protein. Further provided is a compound disclosed herein, for use in simultaneous, separate, or sequential combination with pemetrexed, for the treatment of cancer, in which the cancer has one or more cells that express a mutant KRAS G12C, G12D, and / or G12V protein. Additionally provided is a combination comprising a compound disclosed herein, and pemetrexed, for simultaneous, separate, or sequential use in the treatment of cancer, in which the cancer has one or more cells that express a mutant KRAS G12C, G12D, and / or G12V protein. As described herein, the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein. Further, a platinum agent can also be administered to the patient (and the platinum agent can be cisplatin, carboplatin, or oxaliplatin). As described herein, the cancer can be colorectal carcinoma in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or
[0302]
[0303] G12V mutant protein or the cancer can be mutant pancreatic cancer in which the cancer has one or more cells that express a KRAS G12C, G12D, and / or G12V mutant protein. This method also includes treating KRAS G12A, G12C, G12D, G12S, G12V and / or G13D mutant bearing cancers of other origins.
[0304]
[0155] In all methods and uses described herein, wherein two or more therapeutic agents are administered, the two or more therapeutic agents may be administered simultaneously, separately, or sequentially.
[0305]
[0156] In an embodiment according to any one of the “use” embodiments immediately above, a crystalline form of the compound disclosed herein is used. In some embodiments, the compound is crystalline Formula I. In a further embodiment, the crystalline form of a compound of Formula I is characterized by having an X-ray powder diffraction (XRPD) pattern comprising peaks in degrees at 20 values of 16.1 ± 0.2. The crystalline form of the compound of Formula I may be further characterized by comprising peaks in degrees at 20 values of 7.7 ± 0.2 and 13.5 ± 0.2. In some embodiments, the compound is crystalline Formula II. In a further embodiment, the crystalline form of a compound of Formula II is characterized by having an X-ray powder diffraction (XRPD) pattern comprising peaks in degrees at 20 values of 7.2 ± 0.2. The crystalline form of a compound of Formula II may be further characterized by comprising peaks in degrees at 20 values of 15.5 ± 0.2 and 19.9 ± 0.2. In some embodiments, the compound is crystalline Formula III. In a further embodiment, the crystalline form of a compound of Formula III is characterized by having an X-ray powder diffraction (XRPD) pattern comprising peaks in degrees at 20 values of 6.8 ± 0.2. The crystalline form of a compound of Formula III may be further characterized by comprising peaks in degrees at 20 values of 13.9± 0.2 and 16.5 ± 0.2.
[0306]
[0157] In some embodiments, the present disclosure is directed to a method for treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the solid pharmaceutical composition disclosed herein (e.g., enteric tablet, enteric capsule). In some embodiments, the cancer has one or more cells that express a mutant KRAS G12A, G12C, G12D, G12S, G12V and / or G13D protein. In some embodiments, a side effect of vomiting in the subject is less than a side effect of vomiting associated with administering a non-enteric capsule composition of the same amount of a compound disclosed herein, such as crystalline Formula I. In some embodiments, a side effect of diarrhea in the subject is less than a side effect of diarrhea associated with administering a capsule composition of the same amount of a compound disclosed herein, such as Formula I. In some embodiments, a
[0307]
[0308] side effect of vomiting or diarrhea in the subject occurs in less than 5% of the total subject population. In some embodiments, a side effect of vomiting or diarrhea in the subject occurs in less than 10 % of the total subject population. In some embodiments, a side effect of vomiting or diarrhea in the subject occurs in less than 15 % of the total subject population. In some embodiments, a side effect of vomiting or diarrhea in the subject occurs in less than 20 % of the total subject population. In some embodiments, a side effect of vomiting or diarrhea in the subject occurs in less than 25 % of the total subject population.
[0309] Further embodiments
[0310]
[0158] The following are further numbered embodiments of the disclosure:
[0311]
[0159] Embodiment 1. An esylate salt of a compound of the formula:
[0312]
[0313]
[0160] Embodiment 2. The salt of embodiment 1 of the formula:
[0314]
[0315]
[0161] Embodiment 3. The salt of embodiment 1 or embodiment 2, wherein the salt is in crystalline form.
[0316]
[0162] Embodiment 4. The salt of embodiment 3, wherein the crystalline form is characterized by having an X-ray powder diffraction pattern comprising a peak in degrees at 20 value of 16.1 ± 0.2.
[0317]
[0163] Embodiment 5. The salt of embodiment 4, wherein the crystalline form is characterized by having an X-ray powder diffraction pattern further comprising peaks in degrees at 20 values of 7.7 ± 0.2 and 13.5 + 0.2.
[0318]
[0164] Embodiment 6. A hydrochloride salt of a compound of the formula:
[0319]
[0320]
[0165] Embodiment 7. The salt of embodiment 6 of the formula:
[0321]
[0322]
[0166] Embodiment 8. The salt of embodiment 6 or embodiment 7, wherein the salt is in crystalline form.
[0323]
[0167] Embodiment 9. The salt of embodiment 8, wherein the crystalline form is characterized by having an X-ray powder diffraction pattern comprising a peak in degrees at 20 value of 6.8 ± 0.2.
[0324]
[0168] Embodiment 10. The salt of embodiment 9, wherein the crystalline form is characterized by having an X-ray powder diffraction pattern further comprising peaks in degrees at 20 values of 13.9+ 0.2 and 16.5 + 0.2.
[0325]
[0169] Embodiment 11. A pharmaceutical composition comprising a salt of any one of embodiments 1-10, and a pharmaceutically acceptable carrier, diluent or excipient.
[0326]
[0170] Embodiment 12. A solid oral pharmaceutical dosage form comprising a core composition, wherein the core composition comprises a compound disclosed herein, and wherein the oral dosage form is a tablet or a capsule.
[0327]
[0171] Embodiment 13. The pharmaceutical dosage form of embodiment 12, wherein the dosage form is enterically coated.
[0328]
[0172] Embodiment 14. A solid oral pharmaceutical dosage form comprising: a) a core composition comprising a compound disclosed herein; b) a capsule that contains the core composition and wherein the capsule has a body and a cap; c) a polymeric seal covering the transition between the capsule cap and body; and d) an enteric coating that coats the polymeric seal and capsule.
[0329]
[0173] Embodiment 15. The pharmaceutical dosage form of any one of embodiments 12-14, wherein the compound is of the formula:
[0330]
[0331] preferably the compound is in crystalline form.
[0332]
[0174] Embodiment 16. The pharmaceutical dosage form of any one of embodiments 12-14, wherein the compound is of the formula:
[0333]
[0334] preferably the compound is in crystalline form.
[0335]
[0175] Embodiment 17. The pharmaceutical dosage form of any one of embodiments 12-14, wherein the compound is of the formula:
[0336]
[0337] preferably the compound is in crystalline form.
[0338]
[0176] Embodiment 18. The pharmaceutical dosage form of any one of embodiments 12-17, wherein the dosage form releases none of the compound in a fluid having pH < 4.5 and releases the majority of the compound in a fluid having pH > 6.0.
[0339]
[0177] Embodiment 19. The pharmaceutical dosage form of any one of embodiments 12-17, wherein the dosage form releases: none of the compounds disclosed herein, for up to 2 hours in fluid having pH between 4.5 and 6.0; and the majority of the compound in fluid having pH > 6.0.
[0340]
[0178] Embodiment 20. The pharmaceutical dosage form of any one of embodiments 12-17, wherein the dosage form releases: none of the compounds disclosed herein, for up to 2 hours in fluid having pH between 4.5 and 6.0; and the majority of the compound in fluid having pH > 6.8.
[0341]
[0179] Embodiment 21. The pharmaceutical dosage form of any one of embodiments 14-20, wherein the polymeric seal comprises the same composition as the enteric coating.
[0342]
[0343] [180J Embodiment 22. The pharmaceutical dosage form of any one of embodiments 14-21, wherein the polymeric seal comprises HPMC.
[0344]
[0181] Embodiment 23. The pharmaceutical dosage form of any one of embodiments 14-22, wherein the polymeric seal is a band.
[0345]
[0182] Embodiment 24. The pharmaceutical dosage form of any one of embodiments 14-23, wherein the enteric coating comprises a copolymer comprising at least one polymer selected from the group consisting of methyl acrylate, methyl methacrylate, methacrylic acid and ethyl acrylate.
[0346]
[0183] Embodiment 25. The pharmaceutical dosage form of any one of embodiments 14-24, wherein the enteric coating comprises a copolymer comprising at least one polymer selected from polymethacrylic acid and ethyl acrylate.
[0347]
[0184] Embodiment 26. The pharmaceutical dosage form of embodiment 24, wherein the methacrylic acid and ethyl acrylate are present in a ratio of about 1:1.
[0348]
[0185] Embodiment 27. The pharmaceutical dosage form of embodiment 25, wherein the enteric coating comprises polymethacrylic acid and ethyl acrylate in a concentration between 10 and 70%.
[0349]
[0186] Embodiment 28. The pharmaceutical dosage form of embodiment 25, wherein the enteric coating comprises polymethacrylic acid and ethyl acrylate in a concentration of about 65%.
[0350]
[0187] Embodiment 29. The pharmaceutical dosage form of any one of embodiments 14-17, wherein the coating further comprises polymethyl acrylate, methyl methacrylate, and methacrylic acid.
[0351]
[0188] Embodiment 30. The pharmaceutical dosage form of embodiment 24, wherein the methyl acrylate, methyl methacrylate and methacrylic acid are present in a ratio of about 7:3:1.
[0352]
[0189] Embodiment 31. The pharmaceutical dosage form of embodiment 29, wherein the enteric coating comprises polymethyl acrylate, methyl methacrylate, and methacrylic acid in a concentration between 40-60%.
[0353]
[0190] Embodiment 32. The pharmaceutical dosage form of embodiment 29, wherein the enteric coating comprises polymethyl acrylate, methyl methacrylate, and methacrylic acid in a concentration of about 52%.
[0354]
[0191] Embodiment 33. The pharmaceutical dosage form of any one of embodiments 14-32, wherein the enteric coating comprises triethyl citrate (TEC).
[0355]
[0192] Embodiment 34. The pharmaceutical dosage form of embodiment 33, wherein the enteric
[0356]
[0357] coating comprises TEC in a concentration of about 3%.
[0358]
[0193] Embodiment 35. The pharmaceutical dosage form of embodiment 33, wherein the enteric coating comprises TEC in a concentration of about 2 %.
[0359]
[0194] Embodiment 36. The pharmaceutical dosage form of any one of embodiments 14-35, wherein the coating level is between 5-20 mg / cm2.
[0360]
[0195] Embodiment 37. The pharmaceutical dosage form of any one of embodiments 14-36, wherein the core composition further comprises a permeation enhancer.
[0361]
[0196] Embodiment 38. The pharmaceutical dosage form of embodiment 37, wherein the permeation enhancer is selected from the group consisting of sodium N-[8-(2 -hydroxybenzoyl) amino] caprylate (SNAC), sodium caprate (CIO), sodium caprylate (C8), and 8-(N-2-hydroxy-5- chlorobenzoyl)-amino-caprylic acid (5-CNAC).
[0362]
[0197] Embodiment 39. The pharmaceutical dosage form of embodiment 37 or 38, wherein the permeation enhancer is CIO.
[0363]
[0198] Embodiment 40. The pharmaceutical dosage form of embodiment 39, wherein the core composition comprises between 1 mg and 100 mg of CIO.
[0364]
[0199] Embodiment 41. The pharmaceutical dosage form of any one of embodiments 14-40, wherein the core composition further comprises microcrystalline cellulose (MCC), preferably the core composition comprises about 66 mg MCC.
[0365]
[0200] Embodiment 42. A solid oral pharmaceutical dosage form comprising: a) a core composition comprising a compound disclosed herein and CIO; b) a capsule that contains the core composition and wherein the capsule has a body and a cap; c) a polymeric seal covering the transition between the capsule cap and body; and d) an enteric coating that coats the polymeric seal and capsule, wherein the coating comprises one or more co-polymers selected from the group consisting of: i) polymethacrylic acid, ethyl acrylate], wherein the methacrylic acid and ethyl acrylate are present in a ratio of about 1:1.; ii) and poly [methyl acrylate, methyl methacrylate, methacrylic acid], wherein the methyl acrylate, methyl methacrylate and methacrylic acid are present in a ratio of about 7:3:1.
[0366]
[0201] Embodiment 43. The pharmaceutical dosage form of embodiment 42, wherein the core composition comprises: (i) a compound disclosed herein; and (ii) about 280 mg CIO; the polymeric seal comprises: (i) about 17% HPMC; (ii) about 58% ethanol; and (iii) about 25% water; and the enteric coating comprises: (i) about 12.9% poly [methacrylic acid, ethyl acrylate], wherein the methacrylic acid and ethyl acrylate are present in a ratio of about 1:1.; (ii) about
[0367]
[0368] 51.6% polymethyl acrylate, methyl methacrylate, methacrylic acidj, wherein the methyl acrylate, methyl methacrylate and methacrylic acid are present in a ratio of about 7:3:1; (iii) about 2.9% TEC; and (iv) about 32.6% water; and wherein the coating level is about 10 mg / cm2.
[0369]
[0202] Embodiment 44. The pharmaceutical dosage form of embodiment 42, wherein the core composition comprises: (i) a compound disclosed herein; (ii) about 280 mg CIO; and (iii) about 66 mg MCC; the polymeric seal comprises: (i) about 17% HPMC; (ii) about 58% ethanol; and (iii) about 25% water; and the enteric coating comprises: (i) about 12.9% poly [methacrylic acid, ethyl acrylate], wherein the methacrylic acid and ethyl acrylate are present in a ratio of about 1:1; (ii) about 51.6% polymethyl acrylate, methyl methacrylate, methacrylic acid], wherein the methyl acrylate, methyl methacrylate and methacrylic acid are present in a ratio of about 7:3: 1; (iii) about 2.9% TEC; and (iv) about 32.6% water; and wherein the coating level is about 10 mg / cm2.
[0370]
[0203] Embodiment 45. The pharmaceutical dosage form of embodiment 42, wherein the core composition comprises: (i) a compound disclosed herein; (ii) about 280 mg CIO; and (iii) about 66 mg MCC; the polymeric seal comprises: (i) about 17% HPMC; (ii) about 58% ethanol; and (iii) about 25% water; and the enteric coating comprises: (i) about 64.5% poly [methacrylic acid, ethyl acrylate], wherein the methacrylic acid and ethyl acrylate are present in a ratio of about 1:1.; (ii) about 2.9% TEC; and (iii) about 32.6% water; and wherein the coating level is about 7 mg / cm2.
[0371]
[0204] Embodiment 46. The pharmaceutical dosage form of any one of embodiments 12-44, wherein the bioavailability of the compound is not negatively impacted if the dosage form is orally administered with food.
[0372]
[0205] Embodiment 47. An enteric pellet comprising a) a core consisting of a compound disclosed herein and one or more pharmaceutically acceptable excipients; b) an optional separating layer comprising a non-reducing sugar and one or more pharmaceutically acceptable excipients; c) an enteric layer comprising hydroxypropylmethylcellulose acetate succinate (HPMCAS) and one or more pharmaceutically acceptable excipients; and d) an optional finishing layer.
[0373]
[0206] Embodiment 48. A pellet of embodiment 47, wherein the HPMCAS is partially neutralized with ammonium ions to the degree that from about 0% to about 25% of the succinic acid groups arc neutralized, preferably the HPMCAS is partially neutralized to the degree that from about 0% to about 15% of the succinic acid groups are neutralized.
[0374]
[0207] Embodiment 49. A pellet of embodiment 47, wherein the separating layer is present.
[0375]
[0376] [208 J Embodiment 50. A pellet of embodiment 47, wherein the average particle size of the compound is about 50 pm or less.
[0377]
[0209] Embodiment 51. A pellet of embodiment 47, wherein the core comprises an inert core on which the compound is deposited as a layer comprising in addition a pharmaceutically acceptable excipient.
[0378]
[0210] Embodiment 52. A pellet of embodiment 47, wherein the separating layer is present.
[0379]
[0211] Embodiment 53. A pellet of embodiment 47, wherein the HPMCAS is partially neutralized with ammonium ions to the degree that from about 0% to about 25% of the succinic acid groups are neutralized.
[0380]
[0212] Embodiment 54. A pellet of embodiment 47, wherein the separating layer comprises a pharmaceutically acceptable sugar.
[0381]
[0213] Embodiment 55. A pellet of embodiment 54, wherein the sugar is sucrose.
[0382]
[0214] Embodiment 56. A solid pharmaceutical composition, comprising: (1) a compound disclosed herein constituting about 30-67% percent by weight of the composition; (2) microcrystalline cellulose constituting about 20-55% by weight of the composition; (3) mannitol constituting about 0-10% by weight of the composition; (4) crospovidone constituting about 2% to about 5% by weight of the composition; (5) colloidal silicon dioxide constituting up to about 0.5-2% by weight of the composition; (6) magnesium stearate constituting about 1-3% by weight of the composition, and (7) an enteric coating.
[0383]
[0215] Embodiment 57. The solid pharmaceutical composition of embodiment 56, wherein the compound is Formula I, preferably crystalline Formula I.
[0384]
[0216] Embodiment 58. The solid pharmaceutical composition of embodiment 56, wherein the compound is Formula II, preferably crystalline Formula II.
[0385]
[0217] Embodiment 59. The solid pharmaceutical composition of embodiment 56, wherein the compound is Formula III, preferably crystalline Formula III.
[0386]
[0218] Embodiment 60. The solid pharmaceutical composition of any one of embodiments 56-59, wherein the solid pharmaceutical composition is in the form of a tablet.
[0387]
[0219] Embodiment 61. The solid pharmaceutical composition of any one of embodiments 56-59, wherein the solid pharmaceutical composition further comprises a film coat.
[0388]
[0220] Embodiment 62. The solid pharmaceutical composition of embodiments 56, wherein (1) the compound disclosed herein constitutes about 33.3% percent of the composition; (2) the microcrystalline cellulose constitutes about 51.2% of the composition; (3) the mannitol
[0389]
[0390] constitutes about 10% of the composition; (4) the crospovidone constitutes about 3% of the composition; (5) the colloidal silicon dioxide constitutes about 1 % of the composition; (6) the magnesium stearate constitutes about 1.5% of the composition, and (7) an enteric coating, wherein all percentages are percentages by weight and wherein the total weight is 100%.
[0391]
[0221] Embodiment 63. The solid pharmaceutical composition of embodiment 62, wherein the solid pharmaceutical composition is in the form of a tablet.
[0392]
[0222] Embodiment 64. The solid pharmaceutical composition of embodiment 63, wherein the solid pharmaceutical composition further comprises a film coat.
[0393]
[0223] Embodiment 65. An oral solid pharmaceutical composition in the form of a tablet comprising: (1) a compound disclosed herein constituting about 33.3% by weight of the composition; (2) microcrystalline cellulose constituting about 51.2% by weight of the composition; (3) mannitol constituting about 10.0% by weight of the composition; (4) crospovidone constituting about 3.0% by weight of the composition; (5) colloidal silicon dioxide constituting about 1.0% by weight of the composition; (6) magnesium stearate constituting about 1.5% by weight of the composition, and (7) an enteric coating.
[0394]
[0224] Embodiment 66. The solid pharmaceutical composition of embodiment 65, wherein the compound is Formula I, preferably crystalline Formula I.
[0395]
[0225] Embodiment 67. The solid pharmaceutical composition of embodiment 65, wherein the compound is Formula II, preferably crystalline Formula II.
[0396]
[0226] Embodiment 68. The solid pharmaceutical composition of embodiment 65, wherein the compound is Formula III, preferably crystalline Formula III.
[0397]
[0227] Embodiment 69. A method of treating cancer in a patient in need thereof, the method comprising administering an effective amount of the salt, compound, crystalline form, pharmaceutical composition, dosage form, pellet or solid pharmaceutical composition of any of the preceding embodiments to a patient.
[0398]
[0228] Embodiment 70. The method of embodiment 69, wherein the patient has a cancer that was determined to have one or more cells expressing the KRAS G12A, G12C, G12D, G12S, G12V and / or G13D mutant proteins prior to administration of the salt, compound, crystalline form, pharmaceutical composition, dosage form, pellet or solid pharmaceutical composition.
[0399]
[0229] Embodiment 71. The method of embodiment 69 or 70, wherein the cancer is non-small cell lung cancer.
[0400]
[0230] Embodiment 72. The method of embodiment 69 or 70, wherein the cancer is colorectal
[0401]
[0402] cancer.
[0403]
[0231] Embodiment 73. The method of embodiment 69 or 70, wherein the cancer is pancreatic cancer.
[0404]
[0232] Embodiment 74. The method of embodiment 69 or 70, wherein one or more cells express KRAS G12A, G12C, G12D, G12S, G12V and / or G13D mutant proteins.
[0405]
[0233] Embodiment 75. A method of treating a patient with a cancer that has a KRAS G12A, G12C, G12D, G12S, G12V and / or G13D mutation comprising administering to a patient in need thereof an effective amount of the salt, compound, crystalline form, pharmaceutical composition, dosage form, pellet or solid pharmaceutical composition of any of the preceding embodiments to a patient.
[0406]
[0234] Embodiment 76. The method of embodiment 75, wherein the cancer is selected from lung cancer, pancreatic cancer, cervical cancer, esophageal cancer, endometrial cancer, mutant ovarian cancer, biliary tract carcinoma (preferably cholangiocarcinoma), multiple myeloma, gastric cancer, and colorectal cancer.
[0407]
[0235] Embodiment 77. The method of embodiment 75 or 76, wherein the cancer is non-small cell lung cancer.
[0408]
[0236] Embodiment 78. The method of embodiment 75 or 76, wherein the cancer is colorectal cancer.
[0409]
[0237] Embodiment 79. The method of embodiment 75 or 76, wherein the cancer is pancreatic cancer.
[0410]
[0238] Embodiment 80. The method of any one of embodiments 69-79, wherein the patient is also administered an effective amount of one or more of a PD- 1 inhibitor, a PD-L1 inhibitor, a CDK4 / CDK6 inhibitor, an EGFR inhibitor, an ERK inhibitor, an Aurora A inhibitor, a SHP2 inhibitor, a platinum agent, and pemetrexed, or pharmaceutically acceptable salts thereof.
[0411]
[0239] Embodiment 81. The salt of any one of embodiments 1-10, for use in therapy.
[0412]
[0240] Embodiment 82. The salt of any one of embodiments 1-10, for use in the treatment of cancer.
[0413]
[0241] Embodiment 83. The salt for use of embodiment 82, wherein the cancer has a KRAS G12A, G12C, G12D, G12S, G12V and / or G13D mutation.
[0414]
[0242] Embodiment 84. The salt for use of embodiment 82 or 83, wherein the cancer is selected from lung cancer, pancreatic cancer, cervical cancer, esophageal cancer, endometrial cancer, ovarian cancer, biliary tract carcinoma (preferably cholangiocarcinoma), multiple myeloma, and
[0415]
[0416] colorectal cancer.
[0417]
[0243] Embodiment 85. The salt for use of embodiment 84, wherein the cancer is selected from lung cancer, pancreatic cancer, ovarian cancer, and colorectal cancer.
[0418]
[0244] Embodiment 86. The salt of any one of embodiments 1-10, for use in simultaneous, separate, or sequential combination with one or more of a PD-1 or PD-L1 inhibitor, a CDK4 / CDK6 inhibitor, an EGFR inhibitor, an ERK inhibitor, an Aurora A inhibitor, a SHP2 inhibitor, a platinum agent, pemetrexed, a folate analog, an antimetabolite, a taxane, and a camptothecin, or pharmaceutically acceptable salts thereof, in the treatment of cancer.
[0419]
[0245] Embodiment 87. The salt of embodiment 86, wherein the cancer is selected from colorectal cancer, pancreatic cancer, and non-small cell lung cancer.
[0420]
[0246] Embodiment 88. A salt of any one of embodiments 1-10 for use in simultaneous, separate, or sequential combination with a PD-1 inhibitor in the treatment of cancer.
[0421]
[0247] Embodiment 89. The salt for use of embodiment 88, wherein the cancer has a KRAS G12A, G12C, G12D, G12S, G12V and / or G13D mutation.
[0422]
[0248] Embodiment 90. The salt for use of embodiment 88 or 89, wherein the cancer is selected from lung cancer, pancreatic cancer, cervical cancer, esophageal cancer, endometrial cancer, ovarian cancer, biliary tract carcinoma (preferably cholangiocarcinoma), multiple myeloma, and colorectal cancer.
[0423]
[0249] Embodiment 91. The salt for use of embodiment 90, wherein the cancer is selected from colorectal cancer, pancreatic cancer, and non-small cell lung cancer.
[0424]
[0250] Embodiment 92. The salt for use of any one of embodiments 88-91, wherein the PD-1 inhibitor is pembrolizumab.
[0425]
[0251] Embodiment 93. A salt of any one of embodiments 1-10 for use in simultaneous, separate, or sequential combination with an EGFR inhibitor in the treatment of cancer.
[0426]
[0252] Embodiment 94. The salt for use of embodiment 93, wherein the cancer has a KRAS G12A, G12C, G12D, G12S, G12V and / or G13D mutation.
[0427]
[0253] Embodiment 95. The salt for use of embodiment 93 or 94, wherein the cancer is selected from lung cancer, pancreatic cancer, cervical cancer, esophageal cancer, endometrial cancer, ovarian cancer, biliary tract carcinoma (preferably cholangiocarcinoma), multiple myeloma, and colorectal cancer.
[0428]
[0254] Embodiment 96. The salt for use of embodiment 95, wherein the cancer is selected from colorectal cancer, pancreatic cancer, and non-small cell lung cancer.
[0429]
[0430] [255J Embodiment 97. The salt for use of any one of embodiments 93-96, wherein the EGER inhibitor is cetuximab.
[0431]
[0256] Embodiment 98. A salt, compound, pharmaceutical composition, dosage form, pellet or solid pharmaceutical composition of any of the prior embodiments, for use in therapy.
[0432]
[0257] Embodiment 99. A salt, compound, pharmaceutical composition, dosage form, pellet or solid pharmaceutical composition of any of the prior embodiments, for use in the treatment of cancer.
[0433]
[0258] Embodiment 100. The use of embodiment 99, wherein the cancer has a KRAS G12A, G12C, G12D, G12S. G12V and / or G13D mutation.
[0434]
[0259] Embodiment 101. The use of embodiment 99 or 100, wherein the cancer is selected from lung cancer, pancreatic cancer, cervical cancer, esophageal cancer, endometrial cancer, ovarian cancer, biliary tract carcinoma (preferably cholangiocarcinoma), multiple myeloma, and colorectal cancer.
[0435]
[0260] Embodiment 102. The use of any one of embodiments 99-101, wherein the cancer is pancreatic cancer.
[0436]
[0261] Embodiment 103. The use of any one of embodiments 99-101, wherein the cancer is colorectal cancer.
[0437]
[0262] Embodiment 104. The use of any one of embodiments 99-101, wherein the cancer is nonsmall cell lung cancer.
[0438]
[0263] Embodiment 105. The dosage form for use according to embodiment 99, wherein the dosage form is administered once daily, twice daily, alternate days, every third day, every fourth day, every fifth day, every sixth day or once weekly.
[0439]
[0264] Embodiment 106. The dosage form for use according to embodiment 105, wherein the dosage form is administered once daily or twice daily.
[0440]
[0265] Embodiment 107. The dosage form for use according to embodiment 105 or 106, wherein the dosage form may be administered with or without food.
[0441]
[0266] Embodiment 108. The dosage fomr for use according to embodiment 105 or 106, wherein the dosage form is administered with food.
[0442]
[0267] Embodiment 109. A method of preparing a salt of embodiments 1-5, the method comprising suspending 2-Amino-4-(3-((S)-3-(dimcthylamino)pyrrolidin-l-yl)-5-fluoro-7,9- dihydrofuro[3,4-f]quinazolin-6-yl)-7-fluorothieno[3,2-c]pyridine-3-carbonitrile in one or more solvents, adding ethanesulfonic acid, and isolating the esylate salt.
[0443]
[0444] [268 J Embodiment 110. The method of embodiment 109, wherein the solvent is one or more of water, acetone, benzyl alcohol (BnOH), tetrahydrofuran (THF), and isopropyl alcohol (IP A).
[0445]
[0269] Embodiment 111. The method of embodiment 109, wherein the solvent comprises water, acetone, and BnOH.
[0446]
[0270] Embodiment 112. The method of embodiment 109, wherein the solvent comprises water and THF.
[0447]
[0271] Embodiment 113. The method of embodiment 109, wherein the solvent comprises water, BnOH, and IPA.
[0448]
[0272] Embodiment 114. The method of embodiment 109, wherein the 2-Amino-4-(3-((S)-3- (dimethylamino)pyrrolidin-l-yl)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-6-yl)-7- fluorothieno[3,2-c]pyridine-3-carbonitrile is dissolved in BnOH at 50° C.
[0449]
[0273] Embodiment 115. A compound of the formula:
[0450]
[0451] Formula I,
[0452] wherein solvent may be optionally present, obtainable by reacting 2-Amino-4-(3-((S)-3- (dimethylamino)pyrrolidin-l-yl)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-6-yl)-7- fluorothieno[3,2-c]pyridine-3-carbonitrile with ethanesulfonic acid.
[0453]
[0274] Embodiment 116. The compound of embodiment 115, wherein the compound is in crystalline form.
[0454]
[0275] Embodiment 117. The compound of embodiment 115, wherein the solvent is one or more of water, acetone, benzyl alcohol (BnOH), tetrahydrofuran (THF), and isopropyl alcohol (IPA).
[0455]
[0276] Embodiment 118. A method of preparing a salt of embodiments 6-10, the method comprising suspending 2-Amino-4-(3-((S)-3-(dimethylamino)pyrrolidin-l-yl)-5-fluoro-7,9- dihydrofuro|3,4-f|quinazolin-6-yl)-7-fluorothieno[3,2-c|pyridine-3-carbonitrile in one or more solvents, adding HC1, and isolating the HC1 salt.
[0456]
[0277] Embodiment 119. The method of embodiment 118, wherein the solvent is 2- methyltetrahydrofuran.
[0457]
[0278] Embodiment 120. A compound of the formula:
[0458]
[0459] Formula III,
[0460] wherein solvent may be optionally present, obtainable by reacting 2-Amino-4-(3-((S)-3- (dimethylamino)pyrrolidin-l-yl)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-6-yl)-7- fluorothieno[3,2-c]pyridine-3-carbonitrile with hydrochloric acid.
[0461]
[0279] Embodiment 121. The compound of embodiment 120, wherein the compound is in crystalline form.
[0462]
[0280] Embodiment 122. A process for preparing the dosage form of any one of embodiments 12 and 14-41, comprising: a) blending all components comprised in the core composition in a suitable blender; b) weighing an amount of the blend formed in step (a) to be the core composition; c) compressing the blend weighed in step (b) using a capsule slug mold; d) placing the slug formed in step (c) into the capsule; e) covering the transition between the capsule cap and body with the polymeric seal; and f) coating the capsule with the enteric coating.
[0463]
[0281] Embodiment 123. A process for preparing an enteric pellet comprising a) providing a core consisting of a compound as disclosed herein and one or more pharmaceutically acceptable excipients; b) optionally, applying to the core a separating layer comprising a non-reducing sugar and one or more pharmaceutically acceptable excipients; c) applying an enteric layer comprising HPMCAS and one or more pharmaceutically acceptable excipients, wherein the HPMCAS is supplied as an aqueous solution or suspension and the application takes place in an apparatus of the fluid bed type; d) optionally, applying a finishing layer.
[0464]
[0282] Embodiment 124. The process of embodiment 123, wherein the compound is of the formula:
[0465]
[0466] Formula I.
[0467]
[0283] Embodiment 125. The process of embodiment 124, wherein the compound is in crystalline
[0468]
[0469] form.
[0470]
[0284] Embodiment 126. The process of embodiment 123, wherein the HPMCAS is fully or partially neutralized with ammonium ions.
[0471]
[0285] Embodiment 127. The process of embodiment 126, wherein the HPMCAS is neutralized to the degree that from about 25% to about 100% of the succinic acid groups are neutralized.
[0472]
[0286] Embodiment 128. The process of embodiment 123, wherein the separating layer is applied.
[0473]
[0287] Embodiment 129. The process of embodiment 128, wherein the separating layer comprises a pharmaceutically acceptable sugar.
[0474]
[0288] Embodiment 130. The process of embodiment 129, wherein the sugar is sucrose.
[0475]
[0289] Embodiment 131. A method of preparing a solid pharmaceutical composition comprising a compound disclosed herein, the method comprising (a) pre-blending, wherein a diluent, a glidant, and a compound disclosed herein are blended together; (b) de-lumping the components of step (a) using a screening mill; (c) blending the components of step (b) with a disintegrant, and a glidant: (d) lubricating by adding a lubricant to the components of step (c); (e) performing a dry granulation of the components of step (d) using a roller compactor, producing a granulated blend; (f) blending a diluent, a disintegrant and a glidant with the granulated blend of step (e); (g) lubricating by adding a lubricant to the components of step (f) to produce a lubricated blend; (h) performing compression by charging the lubricated blend of step (g) to a rotary tablet press and compressing the lubricated blend into tablet cores; and (i) performing enteric film coating by charging the core tablets of step (h) into a pan coater and adding an enteric film coating agent.
[0476]
[0290] Embodiment 132. The process of embodiment 131, wherein the compound is of the formula:
[0477]
[0478] Formula 1.
[0479]
[0291] Embodiment 133. The process of embodiment 132, wherein the compound is in crystalline form.
[0480]
[0292] Embodiment 134. The methods of treatment and uses in therapy, as described above, wherein nausea in the patient receiving the treatment or therapy with an enterically coated dosage
[0481]
[0482] form comprising a compound disclosed herein, preferably crystalline Formula I, is less than the nausea associated with administering a non-enterically coated dosage form of the same amount of the compound.
[0483]
[0293] Embodiment 135. The methods of treatment and uses in therapy, as described above, wherein vomiting in the patient receiving the treatment or therapy with an enterically coated dosage form comprising a compound disclosed herein, preferably crystalline Formula I, is less than the vomiting associated with administering a non-enterically coated dosage form of the same amount of the compound.
[0484]
[0294] Embodiment 136. A compound of a formula
[0485]
[0486] or a pharmaceutically acceptable salt thereof.
[0487]
[0295] Embodiment 137. A compound of a formula
[0488]
[0489]
[0296] Embodiment 138. A compound of a formula
[0490]
[0491] or a pharmaceutically acceptable salt thereof.
[0492]
[0297] Embodiment 139. A compound of a formula
[0493]
[0494] or a pharmaceutically acceptable salt thereof.
[0495]
[0298] Embodiment 140. A compound of a formula
[0496]
[0497] or a pharmaceutically acceptable salt thereof.
[0498]
[0299] Embodiment 141. A method of preparing a compound of a formula
[0499]
[0500] or a pharmaceutically acceptable salt thereof, the method comprising:
[0501] (a) combining a mixture of
[0502]
[0503] (S )-N,N-dimethy Ipy rrolidin- 3 - amine ; and
[0504] (b) deprotecting the product from step (a) under acidic conditions (e.g., HC1).
[0505]
[0300] Embodiment 142. The method of embodiment 141, wherein the product from step (a) is
[0506]
[0507]
[0301] Embodiment 143. A method of preparing a compound of a formula
[0508]
[0509] or a pharmaceutically acceptable salt thereof, the method comprising:
[0510] combining
[0511]
[0512] F with a reducing agent (e.g., sodium borohydride).
[0513]
[0302] Embodiment 144. A method of preparing a compound of a formula
[0514]
[0515] or a pharmaceutically acceptable salt thereof, the method comprising:
[0516] combining
[0517]
[0518] F with a catalyst (e.g., Pd(DPEPhos)C12) and a boron reagent (e.g., bis(ncopcntyl glycolato)diboron (B2ncp2)).
[0519]
[0520] Examples
[0521] X-Ray Powder Diffraction (XRPD)
[0522]
[0303] The XRPD patterns were obtained on a Broker D8 Endeavor X-ray powder diffractometer, equipped with a CuKa (1.5418 A) source and a Linxeye detector, operating at 40 kV and 40 mA. The sample was scanned between 4° and 42° 20, with a step size of 0.009° 20 and a scan rate of 0.5 seconds / step, and using 0.3° primary slit opening, and 3.9° PSD opening. The dry powder was packed on a quartz or silicon sample holder and a smooth surface was obtained using a glass slide. The crystal form diffraction patterns were collected at ambient temperature and relative humidity. Crystal peak positions were determined in MDI-Jade after whole pattern shifting based on an internal NIST 675 standard with peaks at 8.853° and 26.774° 20.
[0523]
[0304] It is well known in the crystallographic art that, for any given crystal form, the relative intensities of the diffraction peaks may vary due to preferred orientation resulting from factors such as crystal morphology and habit. Where the effects of preferred orientation are present, peak intensities are altered, but the characteristic peak positions of the polymorph are unchanged. See, e.g. The United States Pharmacopeia #23, National Formulary #18, pages 1843-1844, 1995. Furthermore, it is also well known in the crystallography art that for any given crystal form the angular peak positions may vary slightly. For example, peak positions can shift due to a variation in the temperature at which a sample is analyzed, sample displacement, or the presence or absence of an internal standard. In the present case, a peak position variability of ± 0.2° 20 is presumed to take into account these potential variations without hindering the unequivocal identification of the indicated crystal form. Confirmation of a crystal form may be made based on any unique combination of distinguishing peaks.
[0524] Preparation of Intermediate 1
[0525] 5,6-Difhioro- 1 ,3-dihydroisobenzofuran
[0526] T
[0527]
[0528] FF
[0529]
[0305] To a mixture of (4,5-difluoro-l,2-phenylene)dimethanol (86 wt%; 1.05 g, 5.19 mmol) in acetonitrile (15.7 mL) under nitrogen was added dimethyl carbonate (2.16 g, 24.0 mmol) followed by sodium methoxide (0.67 g, 12.40 mmol) in one portion. The reaction mixture was
[0530]
[0531] brought to reflux and stirred for -160 minutes, then allowed to cool to room temperature. The mixture was diluted with water (50 mL) and extracted with n-heptane (2 x 25 mL). The combined organic extracts were filtered through diatomaceous earth, rinsing with n-heptane (25 mL), and the filtrate was concentrated under reduced pressure to give the title compound (0.49 g, 57%) as a white solid. ’ll NMR (400 MHz, CDC13) 57.01 (t, J = 8.3 Hz, 2H), 5.03 (s, 4H) ppm.
[0532] Preparation of Intermediate 2
[0533] 5,6-Difluoroisobenzofuran-l(3H)-one
[0534] ZO
[0535]
[0536] F
[0537]
[0306] A mixture of 4,5-difluoro-2-methylbenzoic acid (40.57 g, 235.7 mmol), citric acid (2.23 g, 11.6 mmol), and 1 -bromopyrrolidine-2, 5-dione (44.89 g, 252.2 mmol) in acetonitrile (812 mL) was sparged with nitrogen for 5 minutes, then held at room temperature overnight. The reaction mixture was irradiated with a 456 nm blue LED lamp for 1 day. The mixture was quenched into a solution of sodium bicarbonate (41.78 g, 497.3 mmol) in water (500 mL), rinsing the reactor with acetonitrile (80 mL). Sodium sulfite (9.27 g, 73.5 mmol) and water (160 mL) were added to the quench mixture, and the mixture was transferred to a separatory funnel with an acetonitrile rinse (80 mL). The upper layer was retained and concentrated under reduced pressure at 50 °C to a total mass of 222 g. The resulting slurry was allowed to cool to room temperature, diluted with a mixture of water (333 mL) and acetonitrile (67 mL), and filtered. The solids were washed with a mixture of water (100 mL) and acetonitrile (20 mL) and dried in a vacuum oven to give the title compound (17.06 g, 43%) as a white solid. ES-MS mJz 171 (M+H)+.
[0538] Preparation of Intermediate 3
[0539] 4,7-Dibromo- 5 , 6-difluoroi sobenzofuran- 1 (3 H) -one
[0540]
[0541] F
[0542]
[0307] A mixture of 5,6-difluoroisobenzofuran-l(3H)-one (2.74 g, 16.0 mmol) in sulfuric acid (41
[0543]
[0544] mL) was treated with l,3-dibromo-5,5-dimethylimidazolidine-2, 4-dione (9.10 g, 31.8 mmol), added in portions over 90 minutes. The reaction mixture was held at 25 °C for 16.5 hours. The mixture was poured into a mixture of ice (200 g) and water (100 g), rinsing the reactor with ice- cold water (50 mL). The resulting slurry was warmed to ambient temperature and filtered. The solids were washed with water (2 x 41 mL) and dried in a vacuum oven at 50 °C to give the title compound (4.27 g, 80%) as a white solid. ES-MS m / z 327, 329, 331 (M+H, diBr)+.
[0545] Preparation of Intermediate 4
[0546] 4,7-Dibromo-5,6-difluoro-l,3-dihydroisobenzofuran
[0547]
[0548] F
[0549]
[0308] A mixture of 4,7-dibromo-5,6-difluoroisobcnzofuran-l(3H)-onc (26.71 g, 81.46 mmol) in toluene (267 mL) was sparged with nitrogen for 10 minutes at room temperature. Indium(III) bromide (2.50 g, 7.05 mmol) was added in one portion, followed by triethylsilane (28.6 mL, 179 mmol) added over 5 minutes. The reaction mixture was heated to 60 °C for 1.25 hours, then allowed to cool to room temperature. Aqueous hydrochloric acid (1.0 M; 53.4 mL, 53.4 mmol) was added over 5 minutes. The mixture was filtered through diatomaceous earth, rinsing with toluene (53.4 mL). The biphasic filtrate was transferred to a separatory funnel, and the aqueous layer was discarded. The organic layer was washed with saturated aqueous sodium chloride (2 x 80 mL) and filtered through diatomaceous earth, rinsing with toluene (80 mL). The filtrate was concentrated under reduced pressure, diluted with n-heptane (80 mL), filtered through diatomaceous earth, rinsing with n-heptane (53.4 mL), and concentrated under reduced pressure at 50 °C to give a slurry. The slurry was diluted with n-heptane (53.4 mL) and cooled to -20 °C. The solids were collected by filtration, washed with n-heptane (53.4 mL) pre-cooled to -20 °C, and dried in a vacuum oven at 50 °C to give the title compound (20.14 g, 78%) as a white solid. 'H NMR (400 MHz, CDCh) 55.14 (s, 4H) ppm.
[0550] Alternate Synthesis of Intermediate 4
[0551] 4, 7-Dibromo-5,6-di fluoro- 1,3-dihydroisobenzofuran
[0552]
[0553]
[0309] A mixture of 5,6-difluoro-l,3-dihydroisobenzofuran (94 wt%; 0.084 g, 0.505 mmol) in sulfuric acid (0.84 mL) was treated with l,3-dibromo-5,5-dimethylimidazolidine-2, 4-dione (0.173 g, 0.605 mmol), added portion-wise over 1 minute. The reaction mixture was stirred at room temperature for 3 hours and 40 minutes. The mixture was quenched by pouring onto ice (8 g), then allowed to warn to room temperature and filtered. The solids were washed with water (2 x 8 mL) and dried in a vacuum oven to give the title compound (86 wt%; 0.119 g, 65%) as an off-white solid. Analytical data in agreement with above.
[0554] Preparation of Intermediate 5
[0555] 7-Bromo-5,6-difluoro-l,3-dihydroisobcnzofuran-4-carboxylic acid
[0556]
[0557]
[0310] A mixture of 4,7-dibromo-5,6-difluoro-l,3-dihydroisobenzofuran (2.04 g, 6.43 mmol) in tetrahydrofuran (20.4 mL) was sparged with nitrogen for 6 minutes, then cooled to 0 °C and placed under nitrogen. Isopropylmagnesium chloride (2.0 M in tetrahydrofuran; 3.86 mL, 7.72 mmol) was added over 11 minutes, and the reaction mixture was stirred at 0 °C for 9 minutes, then cooled to -78 °C. Freshly crushed solid carbon dioxide (10 g) was added in portions over 1 minute. The mixture was allowed to warm to room temperature as the excess carbon dioxide sublimed. The mixture was quenched by pouring into aqueous hydrochloric acid (1.0 M; 40 mL) and extracted with ethyl acetate (2 x 20 mL). The combined organic extracts were washed with saturated aqueous sodium chloride (20 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure to give the title compound (83 wt%; 1.75 g, 81%) as a tan solid. ES-MS m / z 277, 279 (M-H, Br)’.
[0558] Preparation of Intermediate 6
[0559] Ethyl (7-bromo-5,6-difluoro-l,3-dihydroisobenzofuran-4-carbonyl)carbamimidothioate
[0560]
[0561]
[0311] A mixture of 7-bromo-5,6-difluoro-l,3-dihydroisobenzofuran-4-carboxylic acid (83 wt%; 1.09 g, 3.25 mmol), diisopropylethylamine (1.21 g, 1.63 mL), ethyl carbamimidothioate hydrobromide (1.27 g, 6.89 mmol), and O-(7-azabenzotriazol-l-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (2.88 g, 7.58 mmol) in acetonitrile (16.3 mL) was stirred at room temperature for 2 hours. Water (65.2 mL) was added, and the resulting slurry was filtered. The solids were washed with water (22 mL) and dried to give the title compound (87 wt%; 0.892 g, 66%) as an off-white solid. ES-MS m / z 365, 367 (M+H, Br)+.
[0562] Preparation of Intermediate 7
[0563] 6-Bromo-3-(cthylthio)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-l-ol
[0564]
[0565]
[0312] A mixture of ethyl (7-bromo-5,6-difluoro-l,3-dihydroisobenzofuran-4- carbonyl)carbamimidothioate (87 wt%; 0.359 g, 0.859 mmol) in N-butylpyrrolidinone (7.2 mL) was flushed with nitrogen, sealed in a vial, and heated at 120 °C for 3 hours. The mixture was allowed to cool to room temperature, and water (14.4 mL) was added dropwise over 5 minutes. The resulting slurry was filtered, and the solids were washed with water (14.4 mL) and dried to give the title compound (94 wt%; 0.277 g, 88%) as a white solid. ES-MS m / z 345, 347 (M+H, Br)+.
[0566] Preparation of Intermediate 8
[0567] 7-Bromo-5,6-di fluoro- l,3-dihydroisobenzofuran-4-carbaldehyde
[0568]
[0569] F
[0570]
[0313] A mixture of 4,7-dibromo-5,6-difluoro-l,3-dihydroisobenzofuran (12.36 g, 39.02 mmol) in
[0571]
[0572] tetrahydrofuran (61.8 mL) was sparged with nitrogen for 5 minutes at room temperature, then cooled to 0 °C. Isopropylmagnesium chloride (2.0 M in tetrahydrofuran; 23.41 mL, 46.82 mmol) was added over 20 minutes while maintaining the internal temperature below 2 °C, then the reaction mixture was held at 0 °C for 39 minutes. Dimethylformamide (9.06 mL, 117 mmol) was added over 3 minutes while maintaining the internal temperature below 8 °C. The reaction mixture was brought to 20 °C and stirred for 2 hours. The mixture was quenched into aqueous hydrochloric acid (1.0 M; 117.1 mL, 117.1 mmol) and diluted with n-heptane (186 mL). The layers were separated, and the organic layer was washed with saturated aqueous sodium chloride (2 x 186 mL), filtered through a pad of sodium sulfate, rinsing with n-heptane (186 mL), and concentrated under reduced pressure. The residue was combined with n-heptane (49.5 mL) and heated to 75 °C. The supernatant was decanted and cooled to 0 °C, and the resulting slurry was filtered. The solids were washed with n-heptane (10 mL) and dried in a vacuum oven at 50 °C to give the title compound (94 wt%; 7.75 g, 71%) as a white solid. ES-MS m / z 263, 265 (M+H, Br)+.
[0573] Preparation of Intermediate 9
[0574] Sodium (7-bromo-5,6-difhroro-l,3-dihydroisobenzofuran-4-yl)(hydroxy)methanesulfonate
[0575]
[0576]
[0314] A mixture of 7-bromo-5,6-difluoro-l,3-dihydroisobenzofuran-4-carbaldehyde (94 wt%; 4.01 g, 14.3 mmol) in acetonitrile (40.1 mL) was treated with a solution of sodium bisulfite / metabisulfite (1.64 g, -15.8 mmol) in water (20.0 mL), added over 3 minutes. The resulting slurry was stirred for 30 minutes, then filtered. The solids were washed with a mixture of acetonitrile (8 mL) and water (4 mL) and dried in a vacuum oven at 60 °C to give the title compound (95 wt%; 3.78 g, 69%) as a white solid. 'H NMR (400 MHz, DMSO-d6) 56.52 (d, J = 4.7 Hz, 1H), 5.47 (apparent dq, J = 13.3, 2.0 Hz, 1H), 5.30 (dd, J = 4.7, 0.8 Hz, 1H), 5.19 (apparent dq, J = 13.4, 2.1 Hz, 1H), 4.90 (apparent q, J = 2.0 Hz, 2H) ppm.
[0577] Preparation of Intermediate 10
[0578] (S)-3-(Dimethylamino)pyrrolidine- 1 -carboximidamide hydrochlorideNHHCI
[0579]
[0580]
[0315] To a mixture of (S)-N,N-dimethylpyrrolidin-3-amine dihydrochloride (20.06 g, 107.2 mmol) and IH-pyrazole-l-carboximidamide hydrochloride (15.72 g, 107.2 mmol) in acetonitrile (201 mL) was added diisopropylethylamine (37.3 mL, 214.4 mmol) over 5 minutes. The mixture was stirred at room temperature overnight. The resulting slurry was cooled in an ice-water bath, and the solids were collected by filtration and washed with chilled acetonitrile (40 mL). The solids were dried in a vacuum oven at 40 °C to give the title compound (15.25 g, 73%) as a white solid. ES-MS in z 157 (M+H)+. 'll NMR (400 MHz, DMSO-de) 57.44 (s, 4H), 3.56 (dd, J = 10.3, 7.0 Hz, 1H), 3.49 (ddd, J = 10.4, 8.7, 2.7 Hz, 1H), 3.30 (td, J = 10.2, 7.0 Hz, 1H), 3.11 (dd, J = 10.3, 8.1 Hz, 1H), 2.82-2.68 (m, 1H), 2.15 (s, 6H), 2.13-2.04 (m, 1H), 1.76 (dtd. J = 12.1, 9.7, 8.7 Hz, 1H) ppm.
[0581] Preparation of Intermediate 11
[0582] (S)-l-(6-Bromo-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-3-yl)-N,N-dimethylpyrrolidin-3- amine
[0583]
[0584]
[0316] A mixture of sodium bicarbonate (0.345 g, 4.11 mmol) and water (0.385 mL) in sulfolane (3.85 mL) was heated to 140 °C in a vial. In a separate vial, 7-bromo-5,6-difluoro-l,3- dihydroisobenzofuran-4-carbaldehyde (94 wt%; 0.128 g, 0.457 mmol) and (S)-3- (dimethylamino)pyrrolidine-l-carboximidamide hydrochloride (0.108 g, 0.554 mmol) in sulfolane (1.28 mL) were also heated to 140 °C. The contents of the second vial were transferred to the first over 1 minute, and the reaction mixture was heated at 140 °C for 20 minutes. The mixture was cooled to room temperature, diluted with water ( 10.3 mL), and extracted with methyl tert-butyl ether (2 x 25 mL). The combined organic extracts were washed with saturated aqueous sodium chloride (25 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was triturated with acetonitrile (3 mL) and filtered, and the solids were washed with acetonitrile (1 mL) and dried in a vacuum oven at 45 °C to give the title
[0585]
[0586] compound (0.011 g, 6%) as a yellow solid. ES-MS m / z 381, 383 (M+H, Br)+.
[0587] Alternate Synthesis of Intermediate 11
[0588] (S)-l-(6-Bromo-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-3-yl)-N,N-dimethylpyrrolidin-3- amine
[0589]
[0590]
[0317] A mixture of sodium bicarbonate (0.205 g, 2.44 mmol), sodium (7-bromo-5,6-difluoro-l,3- dihydroisobenzofuran-4-yl)(hydroxy)methanesulfonate (95 wt%; 0.213 g, 0.553 mmol), and (S)- 3-(dimethylamino)pyrrolidine-l-carboximidamide hydrochloride (0.127 g, 0.652 mmol) in dimethylformamide (4.26 mL) and water (0.213 mL) was flushed with nitrogen, sealed in a vial, and heated at 120 °C for 3 hours. The vial was transferred to a 50 °C heating block and water (8.5 mL) was added. The mixture was allowed to cool to room temperature, then extracted with methyl tert-butyl ether (2 x 50 mL). The combined organic extracts were washed with saturated aqueous sodium chloride (2 x 25 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was triturated with acetonitrile (3 mL) and filtered, and the solids were washed with acetonitrile (2 mL) and dried in a vacuum oven at 50 °C to give the title compound (0.034 g, 16%) as a yellow solid. ES-MS m / z 381, 383 (M+H, Br)+.
[0591] Preparation of Intermediate 12
[0592] (S)-l-(5-Lluoro-6-(4,4,5,5-tctramcthyl-l,3,2-dioxaborolan-2-yl)-7,9-dihydrofuro[3,4- f]quinazolin-3-yl)-N,N-dimethylpyrrolidin-3-amine
[0593]
[0594]
[0318] A mixture of (S)-l-(6-bromo-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-3-yl)-N,N- dimethylpyrrolidin-3-amine (1.00 g, 2.62 mmol), bis(triphenylphosphine)palladium(II) dichloride (0.037 g, 0.052 mmol), bis(pinacolato)diborane (0.733 g, 2.885 mmol), and potassium trimethylacetate (0.736 g, 5.246 mmol) in toluene (20 mL) was sparged with nitrogen for 40
[0595]
[0596] minutes. The reaction mixture was heated at 100 °C for 19.3 hours. Toluene (10 mL) was added, and the mixture was heated at 80 °C for 20 minutes, then filtered. The filtrate was concentrated under reduced pressure, and methyl tert-butyl ether (20 mL) was added. The mixture was concentrated under reduced pressure again, and methyl tert-butyl ether (20 mL) was added. The mixture was cooled to 0 °C, and the resulting slurry was filtered. The solids were dried in a vacuum oven to give the title compound (1.03 g, 92%) as a yellow solid. ES-MS m / z 347 (M+H, boronic acid under LCMS conditions)4-.
[0597] Preparation of Intermediate 13
[0598] tert-Butyl (3-cyano-4-(3-((S)-3-(dimethylamino)pynohdin-l-yl)-5-fluoro-7,9-dihydrofuro[3,4- f]quinazolin-6-yl)-7-fluorothieno[3,2-c]pyridin-2-yl)carbamate
[0599]
[0600]
[0319] The title compound can be prepared as described in WO 2024 / 206766 (International patent application number PCT / US2024 / 022154).
[0601] Alternate Synthesis of Intermediate 13
[0602] tert-Butyl (3-cyano-4-(3-((S)-3-(dimethylamino)pyrrolidin-l-yl)-5-fluoro-7,9-dihydrofuro[3,4- f]quinazolin-6-yl)-7-fluorothieno[3,2-c]pyridin-2-yl)carbamate
[0603]
[0604]
[0320] A mixture of (S)-l-(5-fluoro-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-7,9- dihydrofuro[3,4-f]quinazolin-3-yl)-N,N-dimcthylpyrrolidin-3-aminc (0.411 g, 0.960 mmol), tertbutyl (4-chloro-3-cyano-7-fluorothieno[3,2-c]pyridin-2-yl)carbamate (0.321 g, 0.979 mmol), and sodium bicarbonate (0.189 g, 2.249 mmol) in tetrahydrofuran (8.22 mL) and water (1.23 mL) was sparged with nitrogen for 3 minutes. XPhos Pd G4 (CAS# 1599466-81-5; 0.060 g, 0.070 mmol) was added, and the mixture was sparged for an additional 5 minutes, then sealed in a vial and heated at 60 °C for 18 hours. The mixture was cooled to ambient temperature, diluted with
[0605]
[0606] water (25 mL), and extracted with ethyl acetate (2 x 25 mL). The combined organic extracts were washed with saturated aqueous sodium chloride (25 mL), dried over sodium sulfate, filtered through diatomaceous earth, and concentrated under reduced pressure. The residue was purified by silica gel chromatography, eluting with 5-15% methanol in dichloromethane, to give the title compound (0.42 g, 74%) as a yellow solid. ES-MS m / z 594 (M+H)+.
[0607] Preparation of Intermediate 14
[0608] 5-Fluoro-6-nitroisobenzofiiran- 1 (3II)-one
[0609] z0
[0610]
[0611]
[0321] A solution of 4-lluoro-2-methyl-5-nitrobenzoic acid (90 kg, 1 equiv), N-bromosuccinimide (1.1 equiv), and citric acid monohydrate (0.05 equiv) in acetonitrile (30 vol) was passed through a continuous flow LED apparatus (440-460 nm) at 28-40 °C. The reaction mixture was quenched with aqueous sodium bicarbonate (~9 vol) followed by aqueous sodium sulfite (-10 vol) and concentrated under reduced pressure to ~25 vol. Aqueous sodium bicarbonate (~2 vol) and ethyl acetate (6.6 vol) were added, and the layers were separated. The aqueous layer was extracted with ethyl acetate (4.5 vol). The combined organic layers were concentrated to 1-2 vol, diluted with water (4 vol), and filtered. The solids were washed with water and dried to give the title compound (86 kg, 85%) as a solid, used without further purification.rH NMR (400 MHz, DMSO-d6) 58.56 (d, J = 6.6 Hz, 1H), 7.98 (d, J = 10.4 Hz, 1H), 5.52 (s, 2H) ppm.
[0612] Preparation of Intermediate 15
[0613] 6-Bromo-3-(ethylthio)-5-fluoro-l,2,7,9-tetrahydrofuro[3,4-f]quinazoline
[0614] Br S
[0615]
[0616] F
[0617]
[0322] A mixture of 6-bromo-l-chloro-3-(ethylthio)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazoline (91.7 kg, 1 equiv) in tetrahydrofuran (10 vol) was purged with nitrogen and heated to 40 °C. Sodium borohydride (1.54 equiv) was added, and the reaction mixture was stirred until complete.
[0618]
[0619] The mixture was cooled to 5 °C, diluted with acetone (0.5 vol) and aqueous hydrochloric acid, filtered, and washed with water and n-heptane. The solids were dried to give the title compound (81.9 kg, 94%) used without further purification. 'll NMR (400 MHz, DMSO-de) 67.85 (s, 1H), 4.97 (d, J = 18.5 Hz, 4H), 4.32 (s, 2H), 3.03 (m, 2H), 1.26 (m, 3H) ppm.
[0620] Preparation of Intermediate 16
[0621] 6-(5,5-Dimethyl-l,3,2-dioxaborinan-2-yl)-3-(ethylthio)-5-fluoro-7,9-dihydrofuro[3,4- fjquinazoline
[0622] N II
[0623] B i '^V I ' "bT "S
[0624] 0 F
[0625]
[0626]
[0323] A mixture of 6-bromo-3-(ethylthio)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazoline (68 kg, 1 equiv), Pd(DPEPhos)C12 (0.02 equiv), potassium acetate (3.0 equiv), and bis(neopentyl glycolato)diboron (1.1 equiv) in degassed 1,4-dioxane (12 vol) was heated at 78 °C for 8 hours, then cooled to 25 °C. Tetrahydrofuran (4 vol) and acetic acid (0.35 vol) were added, and the mixture was adjusted to 40 °C and filtered, rinsing with tetrahydrofuran (2 x 2 vol). The filtrate was concentrated under reduced pressure to 3 vol, diluted with tetrahydrofuran (3 vol), and concentrated under reduced pressure to 3 vol. The mixture was diluted with methyl tert-butyl ether (4 vol), concentrated under reduced pressure, and diluted with methyl tert-butyl ether (10 vol). The mixture was filtered. The solids were rinsed with methyl tert-butyl ether, and dried at 40 °C to give the title compound (61 kg, 83%) as a solid. 'll NMR (400 MHz, CDC13) 58.99 (s, 1H), 5.45 (s, 2H), 5.32 (m, 2H), 3.86 (s, 4H), 3.31 (m, 2H), 1.51 (t, J = 7.6 Hz, 3H), 1.09 (s, 6H) ppm.
[0627] Preparation of Intermediates 17 and 18
[0628] tert-Butyl (3-cyano-4-(3-(ethylsulfinyl)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-6-yl)-7- fluorothieno[3,2-c]pyridin-2-yl)carbamate and tert-Butyl (3-cyano-4-(3-(ethylsulfonyl)-5-fluoro- 7,9-dihydrofuro[3,4-f]quinazolin-6-yl)-7-fluorothieno[3,2-c]pyridin-2-yl)carbamate
[0629]
[0630]
[0324] A mixture of tert-butyl (3-cyano-4-(3-(ethylthio)-7,9-dihydrofuro[3,4-f]quinazolin-6-yl)-7- fluorothieno[3,2-c]pyridin-2-yl)carbamate (94 kg, 1 equiv) in tetrahydrofuran (12 vol) was cooled to -5 °C. Hydroxy(tosyloxy)iodobenzene (1.6 equiv) was added, and the reaction mixture was stirred for 4 hours. Isopropyl acetate (15 vol) was added dropwise, and the mixture was aged for no less than 8 hours at -5 °C. The mixture was filtered and washed with isopropyl acetate. The solids were triturated in isopropyl acetate (9 vol) at 25 °C, filtered, rinsed with isopropyl acetate, and dried to give the title compound as a mixture of the title compounds (sulfone and sulfoxide; 89.7 kg, 88%). 'll NMR (400 MHz, DMSO-d6) 59.93 (s, 1H), 8.68 (s. 1H), 5.60 (m, 2H), 5.31 (d, J = 14.4 Hz, 1H), 4.97 (d, J = 12 Hz, 1H), 3.76-3.70 (m, 2H), 1.51 (s, 9H), 1.32- 1.29 (t, J = 12 Hz, 3H) ppm and ‘H NMR (400 MHz, DMSO-de) 59.79 (s, 1H), 8.68 (s, 1H), 5.63 (m, 2H), 5.27 (m, 1H), 4.93 (m, 1H), 3.36 (s, 1H), 1.96 (d, J = 20 Hz, 1H), 1.52 (s, 9H), 1.18 (m, 3H), 1.04 (m, 1H) ppm.
[0631] Example 1
[0632] 2-Amino-4-(3-((S)-3-(dimethylamino)pyrrolidin-l-yl)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin- 6-yl)-7-fluorothieno[3,2-c]pyridine-3-carbonitrile (crystalline Formula II)
[0633]
[0634]
[0325] / ert-Butyl (3-cyano-4-(3-((S)-3-(dimethylamino)pyrrolidin-l-yl)-5-fluoro-7,9- dihydrofuro[3,4-f]quinazolin-6-yl)-7-fluorothieno[3,2-c]pyridin-2-yl)carbamate (31.6 kg, 53.2 mol) and aqueous HO (1.5M; 8 volumes) were combined. The mixture was heated to 50 °C and stirred for 7 h. The mixture was cooled to 35 °C and aqueous NaOH (6M; 5 volumes) was added, to adjust the pll to -11-13. Methanol (10.3 volumes) was added and the mixture was stirred at 35 °C for 16 h. The mixture was filtered and the solids were washed with methanol (1.6 volumes). The solids were combined with a solvent mixture (dimethylformamide: water 9:1; 10 volumes).
[0635]
[0636] The mixture was heated to 55 °C and stirred for 2 h. The mixture was cooled to 25 °C over 2 h, then stirred for 16 h. The mixture was filtered and the solids were washed with dimethylformamide: water (4:1, 3 volumes) and water (5 volumes). The solids were dried at 45 °C for 2 days to afford crystalline Formula II as a free base (23.5 kg, 89%).
[0637] XRPD of Crystalline Formula II
[0638]
[0326] A prepared sample of the crystalline free base form (i.e., crystalline Formula II) is characterized by an XRPD pattern using CuKa radiation as having diffraction peaks (degrees 2- theta) as described in Table 2 below and Figure 1, and in particular having a peak at 7.2 degrees in combination with one or more of the peaks selected from the group consisting of 15.5 and 19.9 degrees; with a tolerance for the diffraction angles of 0.2 degrees.
[0639] Table 2. X-ray powder diffraction peaks of Crystalline Formula II Angle (°2-Theta) Relative Intensity
[0640] Peak
[0641] + / - 0.2° (% of most intense peak)
[0642] 1 7.2 100%
[0643] 2 11.7 36.9%
[0644] 3 13.3 16.3%
[0645] 4 14.6 31.8%
[0646] 5 15.5 53.3%
[0647] 6 17.2 18.5%
[0648] 7 18.5 28.8%
[0649] 8 19.2 21.2%
[0650] 9 19.9 63.5%
[0651] 10 25.1 51.1%
[0652]
[0653] 11 25.8 34.4%
[0654] Example 2
[0655] 2-Amino-4-(3-((S)-3-(dimethylamino)pyrrolidin-l-yl)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin- 6-yl)-7-fluorothieno[3,2-c]pyridine-3-carbonitrile ethanesulfonate (crystalline Formula I)
[0656]
[0657]
[0658]
[0327] 2-Amino-4-(3-((S)-3-(dimethylamino)pyrrolidin-l-yl)-5-fluoro-7,9-dihydrofuro[3,4- f]quinazolin-6-yl)-7-fluorothieno[3,2-c]pyridine-3-carbonitrile (3.0 g, 6.1 mmol) and ethanesulfonic acid (0.55 mL, 7.5 mmol) were suspended in benzyl alcohol (10.3 mL). The mixture was heated to 50 °C. Water (4 mL) was added and the complete dissolution of solids was observed. Acetone (2 volumes) was added, then additional acetone (10 volumes) was added over 8 h. The temperature was held at 50 °C for 2 h, then decreased to 25°C over 2 h. The mixture was stirred overnight, then filtered. The solids were washed with acetone (2 x 2 volumes), then dried at 50 °C under vacuum to afford crystalline Formula I (2.98 g, 81%).
[0659] Alternate Synthesis of Crystalline Formula I
[0660] 2-Amino-4-(3-((S)-3-(dimethylamino)pyrrolidin-l-yl)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin- 6-yl)-7-fluorothieno[3,2-c]pyridine-3-carbonitrile ethanesulfonate (crystalline Formula I)
[0661]
[0662]
[0328] 2-Amino-4-(3-((S)-3-(dimethylamino)pyrrolidin-l-yl)-5-fluoro-7,9-dihydrofuro[3,4- f]quinazolin-6-yl)-7-fluorothieno[3,2-c]pyridine-3-carbonitrile (94.4 wt%; 20 g, 38.3 mmol) was suspended in 10% water in tetrahydrofuran (460 mL, 23 volumes). The mixture was heated to 55 °C. Ethanesulfonic acid (4.68 mL, 57.4 mmol) was added and the complete dissolution of solids was observed. The temperature was held at 55 °C for 1 h, then decreased to room temperature. The mixture was stirred overnight, then filtered. The solids were washed with 5% water in tetrahydrofuran (2 x 50 mL), then dried at 45 °C under vacuum to afford crystalline Formula I (98.3% purity; 21.37 g, 91%).
[0663] Alternate Synthesis of Crystalline Formula I
[0664] 2-Amino-4-(3-((S)-3-(dimethylamino)pyrrolidin-l-yl)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin- 6-yl)-7-fhiorothieno[3,2-c]pyridine-3-carbonitrile ethanesulfonate (crystalline Formula I)
[0665]
[0666]
[0667] [329J 2-Amino-4-(3-((S)-3-(dimethylamino)pyrrolidin-l-yl)-5-fluoro-7,9-dihydrofuro[3,4- f]quinazolin-6-yl)-7-fluorothieno[3,2-c]pyridine-3-carbonitrile (22.9 kg, 46.4 mol) and ethanesulfonic acid (5.6 kg, 50.8 mol) were suspended in a solvent mixture (waterbenzyl alcohol: isopropanol 1: 1:0.6; 10 volumes) at 25 °C. The complete dissolution of solids was observed. The mixture was stirred for 1 h, then isopropanol (4 volumes) was added and seed Crystalline Formula I (0.58 kg, 2.5%) was added. The mixture was stirred for 24 h, then additional isopropanol (24 volumes) was added over 10 h at 15-25 °C. The temperature was held at 15-25 °C for 13 h, then filtered. The solids were washed with isopropanol (3 x 2.5 volumes) to afford crystalline Formula I (26.4 kg, 96%).
[0668] Alternate Synthesis of Crystalline Formula I
[0669] 2-Amino-4-(3-((S)-3-(dimethylamino)pyrrolidin-l-yl)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin- 6-yl)-7-fluorothieno[3,2-c]pyridine-3-carbonitrile ethanesulfonate (crystalline Formula I)
[0670]
[0671]
[0330] A mixture of tert-butyl (3-cyano-4-(3-((S)-3-(dimethylamino)pyrrolidin-l-yl)-5-fluoro-7,9- dihydrofuro[3,4-f]quinazolin-6-yl)-7-fluorothieno[3,2-c]pyridin-2-yl)carbamate (4.05 g, 6.82 mmol) in 3: 1 acetonitrile / water (10 L / kg of limiting reagent) was treated with ethanesulfonic acid (3.90 g, 35.4 mmol) and held for 12 hours. In a separate vessel, ethanesulfonic acid (1.734 mL) was dissolved in isopropanol (90 mL). A portion of this isopropanol / ethanesulfonic acid solution (3.75 L / kg of limiting reagent) was added to the reaction mixture over 8 hours. The mixture was seeded (0.103 g), and the remaining isopropanol / ethanesulfonic acid solution (11.25 L / kg) was added dropwise over 16 hours. The mixture was filtered to afford crystalline Formula I (3.36 g, 82%). ES-MS mJz 494 (M+H)+.
[0672] XRPD of Crystalline Formula I
[0673]
[0331] A prepared sample of the crystalline Formula I is characterized by an XRPD pattern using CuKa radiation as having diffraction peaks (degrees 2-theta) as described in Table 3 below and Figure 2, and in particular having a peak at 16.1 degrees in combination with one or more of the peaks selected from the group consisting of 7.7 and 13.5 degrees; with a tolerance for the
[0674]
[0675] diffraction angles of 0.2 degrees.
[0676] Table 3. X-ray powder diffraction peaks of Crystalline Formula I Angle (°2-Theta) Relative Intensity
[0677] Peak + / - 0.2° (% of most intense peak)
[0678] 1 6.3 8.3%
[0679] 2 7.7 33.5%
[0680] 3 13.0 10.3%
[0681] 4 13.5 42.9%
[0682] 5 15.5 17.6%
[0683] 6 16.1 100%
[0684] 7 16.9 12.1%
[0685] 8 19.1 24.2%
[0686] 9 22.6 21.1%
[0687] 10 23.3 14.3%
[0688] 11 24.3 24.1%
[0689]
[0690] 12 26.2 25.4%
[0691] Example 3
[0692] 2-Amino-4-(3-((S)-3-(dimethylamino)pyrrolidin-l-yl)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin- 6-yl)-7-fluorothieno[3,2-c]pyridine-3-carbonitrile hydrochloride (crystalline Formula III)
[0693]
[0694]
[0332] 2-Amino-4-(3-((S)-3-(dimethylamino)pyrrolidin-l-yl)-5-fluoro-7,9-dihydrofuro[3,4- f]quinazolin-6-yl)-7-fluorothieno[3,2-c]pyridine-3-carbonitrile (1.09 g, 2.21 mmol) was suspended in 2-methyltetrahydrofuran (18 mL). HC1 (IM in ethyl acetate; 2.65 mL, 2.65 mmol) was added. The mixture was stirred at 55 °C for 2 h, then cooled to room temperature and stirred for 2.5 days. The solids were filtered and dried at 55 °C under vacuum to afford crystalline Formula III.
[0695] XRPD of Crystalline Formula III
[0696]
[0333] A prepared sample of the crystalline Formula III is characterized by an XRPD pattern
[0697]
[0698] using CuKa radiation as having diffraction peaks (degrees 2-theta) as described in fable 4 below and Figure 3, and in particular having a peak at 6.8 degrees in combination with one or more of the peaks selected from the group consisting of 13.9 and 16.5 degrees; with a tolerance for the diffraction angles of 0.2 degrees.
[0699] Table 4. X-ray powder diffraction peaks of Crystalline Formula
[0700] III
[0701] Angle (°2-Theta) Relative Intensity
[0702] Peak + / - 0.2° (% of most intense peak)
[0703] 1 6.8 100%
[0704] 2 8.4 23.3%
[0705] 3 13.9 36.4%
[0706] 4 14.9 35.5%
[0707] 5 16.5 43.3%
[0708] 6 21.6 26.0%
[0709] 7 22.8 19.8%
[0710] 8 24.9 76.1%
[0711]
[0712] 9 25.8 37.1%
[0713] Example 4
[0714]
[0334] The effect of crystalline Formula II on cell proliferation and ERK phosphorylation was evaluated in a panel of human cancer cell lines harboring diverse KRAS mutations. The GI50 values of cell proliferation inhibition and the IC50 values of phospho-ERK inhibition are summarized in Table 5.
[0715] Cell proliferation assay method
[0716]
[0335] Cells were plated in 50 pl of appropriate growth medium at 700 cells per well in a 384-well cell culture plate (Falcon # 353988, white flat bottom) and incubated overnight at 37°C in 5% CO2 (except SW 1116). SW 1116 cells were incubated overnight at 37°C without CO2. The day after plating, the cells were treated with serially diluted Formula II using a Tecan D300e Digital Dispenser (HP Inc., CA, USA) and incubated at 37°C. Following incubation of the cells with compound for two cell population doubling times, an equal volume of Cell Titer-Gio reagent (Promega #G7571) was added to each well. The plates were shaken at 300 RPM for 10 minutes at room temperature and the luminescent signal was measured with a Perkin Elmer Envision instrument (Revvity, MA, USA).
[0717]
[0336] The cell proliferation % inhibition for each drug-treated well was calculated as:
[0718]
[0719] CTG ( drug treatment) Average CTG of Day 0
[0720] % Cell Proliferation Inhibition = ( 1 x 100%
[0721] CTG so treatment) ~ Avei age CTG of Day 0
[0722]
[0337] The % inhibition data were entered into GraphPad Prism 10 and fitted to 4-parameter logistic fit. GI50 was calculated by interpolating the concentration of compound required at 50% inhibition. Results are summarized in Table 5.
[0723] Phospho-ERK alphaLISA assay method
[0724]
[0338] The effects of Formula II on ERK phosphorylation was measured using the AlphaLISA SureFire Ultra kit (Revvity #MPSU-PTERK-K50K). The cells were plated in 100 pl of appropriate growth medium at 40,000 cells per well in a 96-well Poly-D-Lysine coated tissue culture plate (Corning #354461) and incubated overnight at 37°C in 5% CO2 (except SW1116). SW1116 cells were incubated overnight at 37°C without CO2. The day after plating, the cells were treated with serially diluted Formula II using a Tecan D300e Digital Dispenser (HP Inc. CA, USA) and incubated at 37°C for 2 hours. Following incubation of the cells with compound for 2 hours, the media was removed and 100 pL / well of lysis buffer, supplied with the kit with 2X protease and phosphatase inhibitors (Thermo Scientific #PI78441), was added to each well, followed by incubation for 30 minutes at room temperature with shaking. Ten pL of cell lysate and five pL of the acceptor bead mix were added to each well of the ProxiPlate 384- well assay plate (Revvity #6008289), and the plates were sealed and incubated at room temperature for 2 hours. Five pL of donor bead mix was then added to each well and the plates were again sealed and incubated at room temperature overnight in the dark. The luminescent signals were captured by reading the plates on a Synergy™ Neo2 Multi-Mode Microplate Reader (Agilent Technologies, Inc., CA, USA) at wavelengths of 615 nm and 545 nm. The 615 nm (Eu) signal corresponds to the phosphor-ERKl / 2 analysis, and the 545 nm (Tb) signal corresponds to the total ERK1 / 2 analysis.
[0725]
[0339] For each well, the phospho-ERK signal was normalized to the total-ERK signal to determine the Ratio and the phospho-ERK Inhibition (%) was calculated as shown below: % ERK Phosphorylation Inhibition = (1 -Ratiorug treatment)) x W()%
[0726] RatlO DM go treatment)
[0727]
[0340] The phospho-ERK Inhibition (%) data were entered into GraphPad Prism 10 and the IC50 values were calculated by fitting the data the same as in the cell proliferation assay. Results are summarized in Table 5.
[0728] 'fable 5: Crystalline Formula II demonstrates potent anti-proliferative and anti-ERK phosphorylation activities in human cancer cell lines with KRAS G12A, G12C, G12D, G12S,
[0729]
[0730] G12V, G13D Mutations or wild-type KRAS amplification
[0731] pERK- KRAS
[0732] Cell Line Histology GI50 Catalog #
[0733] Mutation (nM) IC50
[0734] (nM)
[0735] ATCC SW1116 G12A Colon 7.0 8.5
[0736] CCL-233 G12A B lymphoblast 3.4 NA ATCC CRL- MM. Is
[0737] 2974 ATCC
[0738] H23 G12C Lung 35.7 3.6
[0739] CRL-5800 ATCC IIPAC G12D Pancreas 33.0 2.7
[0740] CRL-2119 SNU-869 G12D Biliary Tract 61.7 12.9 KCLB 869
[0741] Carcinoma
[0742] Co ATCC
[0743] LS-123 G12S lon 270 7.8
[0744] CCL-255 ATCC
[0745] H727 G12V Lung 25.1 13.9
[0746] CRL-5815 ATCC
[0747] H747 G13D Colon 12.3 6.8
[0748] CCL-252 WT- JCRB KURAMOCHI Ovary 12.3 12.8
[0749]
[0750] amplification 0098
[0751]
[0341] The results in the above Table 5 indicate crystalline Formula II is potent in cell lines with diverse KRAS-mutant (KRAS G12A, G12C, G12D, G12S, G12V, G13D) and wild type KRAS- amplification across various tumor types.
[0752] Example 5
[0753]
[0342] The solubility of crystalline Formula II and crystalline Formula I were evaluated across a broad range of pH conditions in aqueous media. The equilibrium solubility results are summarized in Table 6.
[0754]
[0343] Aqueous media and a small amount of material (typically 1-3 mg) were combined in a vial to obtain a concentration of 2 mg / mL. The vial was tightly capped and agitated (rotation of at least 180 degrees) to ensure all material made contact with the media. The vial was agitated overnight for a minimum of 16 hr (24 hr target). The material was filtered through a 0.22 pm or 0.45 pm filter and the filtrate was analyzed by HPLC and compared to a calibration curve.
[0755]
[0756] Table 6
[0757] Crystalline Formula II Crystalline Formula I Media
[0758] Concentration (mg / mL) Concentration (mg / mL) 0.1 N Aqueous HC1 >2.00 0.136 0.01 N Aqueous HC1 >2.00 0.202 Simulated Gastric Fluid 0.667 0.242 Water 0.0002 1.83
[0759] pH 4.5 Acetate Buffer 0.094 >2.00 Simulated Intestinal Fluid (Fed) 0.529 0.245 Simulated Intestinal Fluid (Fasted) 0.003 0.171
[0760] pH 6.0 Phosphate Buffer 0.006 0.231
[0761] pH 7.5 Phosphate Buffer 0.0005 0.049
[0762]
[0763]
[0344] The above Table 6 contains comparative solubility data for crystalline Formula II and crystalline Formula I. It is expected that the improved solubility of crystalline Formula I, when compared to crystalline Formula II, will facilitate the administration of a higher dose of crystalline Formula I, if necessary. Crystalline Formula I immediately and completely dissolves in the stomach.
[0764] Example 6
[0765]
[0345] Beagle Dogs were orally dosed in a cross-over animal pharmacokinetic study with crystalline Formula I at -10 mg / kg filled in capsules (enteric and non-cntcric). For fasted groups, animals were fasted overnight, dosed with pentagastrin at 6 pg / kg IM at 30 minutes to 1 hour prior to capsule dosing, and offered food 2 hours post-dosing. For fed groups, animals were fasted overnight, and food was returned at 1 hour (± 15 minutes) prior to capsule dosing.
[0766]
[0346] Blood samples were collected at 0.25, 0.5, 1, 2, 4, 8, 24, 48, and 72 hours for oral dosing. Clinical observations were performed daily beginning three days before the first dose. Animals were observed closely for the first hour post dose, and any adverse event (such as emesis) was recorded as soon it was observed. Additionally, animals were observed closely for 4 hours after dosing for the presence of adverse clinical signs. Body weights were taken prior to each dosing.
[0767]
[0347] Plasma concentrations of Formula I were analyzed using a LC-MS / MS method at IQVIA Laboratories (Indianapolis). ThermoFisher Watson version 7.7.1 was used for pharmacokinetic
[0768]
[0769] calculations. The following pharmacokinetic parameters were calculated from the plasma concentration versus time data: AUCiast, Cmax and tmax.
[0770]
[0348] The results are summarized in Tables 7-9.
[0771] Table 7: Summary of Emesis Events (Time after dosing and Amount) in Fasted Dogs Non-enteric Capsules Enteric Capsules
[0772] Animal
[0773] (Fasted) (Fasted)
[0774] 1 None None
[0775] 2 27 min (5 mL) 34 min (15-20 mL)
[0776] 32 min (5 mL)
[0777] 3 120 min (“White”)
[0778] 58 min (20 mL)
[0779] 4 35 min (5 mL) None
[0780] 5 33 min (20 mL) 119 min (“White”)
[0781] 20 min (5 mL)
[0782] 6 47 min (5-10 mL)
[0783] 24 min (3 mL)
[0784] 34 min (5 mL)
[0785] 43 min (5 mL) 59 min (5 mL)
[0786] 7
[0787] 49 min (10 mL) 105 min (10-20 mL)
[0788] 57 min (10 mL)
[0789] 8 28 min (20 mL) 66 min (25 mL)
[0790] 23 min (30 mL) 42 min (20 mL)
[0791] 27 min (10 mL) 50 min (10 mL)
[0792] 9
[0793] 35 min (10 mL) 58 min (10 mL)
[0794] 52 min (20 mL) 105 min (5-10 mL)
[0795] 34 min (20 mL)
[0796] 10 41 min (15 mL)
[0797] 46 min (10 mL)
[0798] 29 min (30 mL)
[0799] 11 None
[0800] 36 min (5 mL)
[0801]
[0802] 12 27 min (20 mL) 25 min ( 15 mL)
[0803] Male Beagle Dogs were dosed with crystalline Formula I (-10 mg / kg, Oral) in Capsules; Non-enteric Capsules = HPMC Capsules; Enteric Capsules = Eudracaps ® Capsules; Amounts of emesis are approximate
[0804]
[0349] The above Table 7 shows that emesis was reduced in fasted dogs dosed with enteric capsules comprising crystalline Formula I compared to non-enteric capsules comprising crystalline Formula I. In particular, three animals that received enteric capsules comprising crystalline Formula I showed no emesis events.
[0805] Table 8: Summary of Emesis Events (Time after dosing and Amount) in Fed Dogs
[0806]
[0807] Non-enteric Capsules Enteric Capsules
[0808] Animal
[0809] (Fasted) (Fasted)
[0810] 1 None None
[0811] 2 None None
[0812] 3 37 min (“Large amount”) 5 min (“Kibble”, “re-ingested”)
[0813] 36 min (10 mL)
[0814] 4 None
[0815] 41 min (5 mL)
[0816] 5 46 min (“Mostly food”) None
[0817] 6 None 16 min (2 mL)
[0818] 7 None 58 min (5 mL)
[0819] 8 37 min (60 mL) None
[0820] 9 57 min (200 mL) None
[0821] 26 min (200 mL)
[0822] 10 None
[0823] 39 min (15 mL)
[0824] 11 None None
[0825]
[0826] 12 None None
[0827] Male Beagle Dogs were dosed with crystalline Formula I (—10 mg / kg, Oral) in Capsules; Non-enteric Capsules = HPMC Capsules;Enteric Capsules = Eudracaps ® Capsules; Amounts of emesis are approximate
[0828]
[0350] The above Table 8 shows that emesis was reduced in fed dogs dosed with enteric capsules comprising crystalline Formula I compared to non-enteric capsules comprising crystalline Formula I. In particular, nine animals that received enteric capsules comprising crystalline Formula I showed no emesis events.
[0829] Table 9: Exposure Data from Plasma Concentration
[0830] AUClast Cmax tmax Dose Form
[0831] (ng.h / mL) (ng / mL) (h) Non-enteric Capsules
[0832] 1976 + 1497 195 + 147 1.4 + 1.0 (Fasted)
[0833] Non-enteric Capsules
[0834] 3107 + 2206 236 + 207 5.0 + 6.3 (Fed)
[0835] Enteric Capsules
[0836] 1968 ± 715 168 ± 63 2.8 ± 2.7 (Fasted)
[0837] Enteric Capsules
[0838] 3285 + 2252 202 + 139 11.2 + 8.0
[0839]
[0840] (Fed)
[0841] Male Beagle Dogs were dosed with crystalline Formula I (—10 mg / kg, Oral) in Capsules; Non-enteric Capsules = HPMC Capsules; Enteric Capsules = Eudracaps ® Capsules
[0351] I'he above Table 9 shows similar exposure and variability, but higher tmax values in enteric
[0842]
[0843] compared to non-enteric capsules comprising crystalline Formula 1.
[0844]
[0352] The above Table 9 also shows higher exposure and delayed tmax in fed compared to fasted animals in both capsule types comprising crystalline Formula I.
[0845] Example 7
[0846]
[0353] Naive Female Cynomolgus Monkeys were orally dosed in a cross-over animal pharmacokinetic study with crystalline Formula I at -30 mg / kg filled in capsules (enteric and non-enteric). For fasted groups, animals were fasted overnight and fed approximately 2 hours post-dosing. For non-fasted groups, animals were fasted overnight and immediately offered food after capsule dosing. All animals were orally dosed with water for injection (WFI) immediately after capsule dosing.
[0847]
[0354] Blood samples were collected at 0.25, 0.5, 1, 2, 4, 8, 24, 48, and 72 hours for oral dosing. Clinical observations were performed twice daily. Clinical observations included mortality, moribundity, general health, emesis, and signs of toxicity. Body weights were taken prior to each dosing.
[0848]
[0355] Plasma concentrations of Formula I were analyzed using a LC-MS / MS method. WinNonlin (Phoenix™, version 8.3) was used for pharmacokinetic calculations. The following pharmacokinetic parameters were calculated from the plasma concentration versus time data: AUClast, C max and t max-
[0356] The results are summarized in Table 10.
[0849]
[0357] No observations of emesis were recorded during the study.
[0850] Table 10: Exposure Data from Plasma Concentration
[0851] AUClast Cmax tmax
[0852] Dose Form
[0853] (ng.h / mL) (ng / mL) (h)
[0854] Non-enteric
[0855] 2630 ± 866 218 ± 84 4.3 ± 2.0 Capsules (Fasted)
[0856] Non-enteric
[0857] 3297 + 1578 297 + 152 5.3 ± 2.1 Capsules (Fed)
[0858] Enteric Capsules
[0859] 2989 ± 648 313 + 124 8.0 ± 8.0 (Fasted)
[0860] Enteric Capsules
[0861] 4213 ± 2738 378 + 284 8.7 ± 7.8
[0862]
[0863] (Fed)
[0864] Naive Female Cynomolgus Monkeys were dosed with crystalline Formula I (-30 mg / kg,
[0865]
[0866] Oral) in Capsules; Non-enteric Capsules = HPMC Capsules; Enteric Capsules = Eudracaps ® Capsules
[0867]
[0358] The above Table 10 shows that enteric capsules have higher exposure and tmax values when compared to non-enteric capsules comprising crystalline Formula I.
[0868]
[0359] The above Table 10 also shows similar exposure in fasted compared to non-fasted animals in both capsule types comprising crystalline Formula I.
Claims
What is Claimed is:
1. An esylate salt of a compound of the formula:
3. The salt of claim 1 or claim 2, wherein the salt is in crystalline form.
4. The salt of claim 3, wherein the crystalline form is characterized by having an X-ray powder diffraction pattern comprising a peak in degrees at 20 value of 16.1 ± 0.2.
5. The salt of claim 4, wherein the crystalline form is characterized by having an X-ray powder diffraction pattern further comprising peaks in degrees at 20 values of 7.7 ± 0.2 and 13.5 ± 0.2.A hydrochloride salt of a compound of the formula:
7. The salt of claim 6 of the formula:
8. The salt of claim 6 or claim 7, wherein the salt is in crystalline form.
9. The salt of claim 8, wherein the crystalline form is characterized by having an X-ray powder diffraction pattern comprising a peak in degrees at 20 value of 6.8 ± 0.2.
10. The salt of claim 9, wherein the crystalline form is characterized by having an X-ray powder diffraction pattern further comprising peaks in degrees at 20 values of 13.9+ 0.2 and 16.5 ± 0.2.
11. A pharmaceutical composition comprising a salt of any one of claims 1-10, and a pharmaceutically acceptable carrier, diluent or excipient.
12. A solid oral pharmaceutical dosage form comprising a core composition, wherein the core composition comprises a salt of any one of claims 1-10, and wherein the oral dosage form is a tablet or a capsule.
13. The pharmaceutical dosage form of claim 12, wherein the dosage form is enterically coated.
14. A solid oral pharmaceutical dosage form comprising: a) a core composition comprising a salt of any one of claims 1-10; b) a capsule that contains the core composition and wherein the capsule has a body and a cap; c) a polymeric seal covering the transition between the capsule cap and body; and d) an enteric coating that coats the polymeric seal and capsule.
15. The pharmaceutical dosage form of any one of claims 12-14, wherein the salt is of the formula:
16. The pharmaceutical dosage form of claim 15, wherein the salt is crystalline.
17. A solid pharmaceutical composition, comprising: (1) a salt of any one of claims 1-10 constituting about 30-67% by weight of the composition; (2) microcrystalline cellulose constituting about 20-55% by weight of the composition; (3) mannitol constituting about 0-10% by weight of the composition; (4) crospovidone constituting about 2% to about 5% by weight of the composition; (5) colloidal silicon dioxide constituting up to about 0.5-2% by weight of the composition; (6) magnesium stearate constituting about 1-3% by weight of the composition, and (7) an enteric coating.
18. The pharmaceutical composition of claim 17, wherein the salt is of the formula:
19. The pharmaceutical composition of claim 18, wherein the salt is crystalline.
20. A method of treating a patient for cancer, comprising administering to a patient in need thereof, an effective amount of a pharmaceutical composition of any one of claims 11-19 or an effective amount of a salt of any one of claims 1-10, wherein the cancer is selected from lung cancer, pancreatic cancer, cervical cancer, esophageal cancer, endometrial cancer, ovarian cancer, biliary tract carcinoma, multiple myeloma, gastric cancer, and colorectal cancer.
21. The method of claim 20, wherein the patient has a cancer that was determined to have one or more cells expressing the KRAS G12A, G12C, G12D, G12S, G12V and / or G13D mutant proteins prior to administration of the salt.
22. The method of claim 20 or claim 21, wherein the cancer is non-small cell lung cancer.
23. The method of claim 20 or claim 21, wherein the cancer is colorectal cancer.
24. The method of claim 20 or claim 21, wherein the cancer is pancreatic cancer.
25. The method of claim 20 or claim 21, wherein one or more cells express KRAS G12A, G12C, G12D, G12S, G12V and / or G13D mutant proteins.
26. A method of treating a patient with a cancer that has a KRAS G12A, G12C, G12D, G12S, G12V and / or G13D mutation comprising administering to a patient in need thereof an effective amount of a salt of any one of claims 1-10.
27. The method of claim 26, wherein the cancer is selected from lung cancer, pancreatic cancer, cervical cancer, esophageal cancer, endometrial cancer, mutant ovarian cancer, biliary tract carcinoma, multiple myeloma, gastric cancer, and colorectal cancer.
28. The method of claim 27, wherein the cancer is non-small cell lung cancer.
29. The method of claim 27, wherein the cancer is colorectal cancer.
30. The method of claim 27, wherein the cancer is pancreatic cancer.
31. The method of any one of claims 20-30, wherein the patient is also administered an effective amount of one or more of a PD-1 inhibitor, a PD-L1 inhibitor, a CDK4 / CDK6 inhibitor, an EGFR inhibitor, an ERK inhibitor, an Aurora A inhibitor, a SHP2 inhibitor, a platinum agent,pemetrexed, a folate analog, an antimetabolite, a taxane, and a camptothecin, or pharmaceutically acceptable salts thereof.
32. The salt of any one of claims 1-10, for use in therapy.
33. The salt of any one of claims 1-10, for use in the treatment of cancer.
34. The salt for use of claim 33, wherein the cancer has a KRAS G12A, G12C, G12D, G12S, G12V and / or G13D mutation.
35. The salt for use of claim 33 or claim 34, wherein the cancer is selected from lung cancer, pancreatic cancer, cervical cancer, esophageal cancer, endometrial cancer, ovarian cancer, biliary tract carcinoma, multiple myeloma, and colorectal cancer.
36. The salt of any one of claims 1-10 for use in simultaneous, separate, or sequential combination with one or more of a PD-1 or PD-L1 inhibitor, a CDK4 / CDK6 inhibitor, an EGFR inhibitor, an ERK inhibitor, an Aurora A inhibitor, a SHP2 inhibitor, a platinum agent, pemetrexed, a folate analog, an antimetabolite, a taxane, and a camptothecin, or pharmaceutically acceptable salts thereof, in the treatment of cancer.
37. The salt for use of claim 36, wherein the cancer is selected from colorectal cancer, pancreatic cancer, and non-small cell lung cancer.
38. A method of preparing a salt of claims 1-5, the method comprising suspending 2-Amino- 4-(3-((S)-3-(dimethylamino)pyrrolidin-l-yl)-5-fhioro-7,9-dihydrofuro[3,4-f]quinazolin-6-yl)-7- fluorothieno[3,2-c]pyridine-3-carbonitrile in one or more solvents, adding ethanesulfonic acid, and isolating the salt.
39. The method of claim 38, wherein the solvent is at least one of water, acetone, benzyl alcohol (BnOH), tetrahydrofuran (THF), and isopropyl alcohol (IPA).
40. The method of claim 38 or claim 39, wherein the solvent is selected from water, BnOH, and IPA.
41. A compound of the formula:wherein solvent may be optionally present, obtainable by reacting 2-Amino-4-(3-((S)-3- (dimethylamino)pyrrolidin-l-yl)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-6-yl)-7- fluorothieno[3,2-c]pyridine-3-carbonitrile with ethanesulfonic acid.
42. The compound of claim 41, wherein the compound is in crystalline form.
43. A compound selected from44. A method of preparing a compound of a formulaor a pharmaceutically acceptable salt thereof, the method comprising:(a) combining(S)-N,N-dimethylpyrrolidin-3-amine; and(b) deprotecting the product from step (a) under acidic conditions.
45. A method of preparing a compound of a formulaor a pharmaceutically acceptable salt thereof, the method comprising:combiningwith a catalyst and a boron reagent.
